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 Summary	
Primary	infection	of	human	cytomegalovirus	(HCMV)	is	rarely	recognized	in	the	immune	
competent	 host,	 and	 seroprevalence	 reaches	 80%	 in	 the	 older	 population.	 Life‐long	
persistence	 is	 the	 hallmark	 of	 HCMV.	 In	 immunocompromised	 patients	 such	 as	 in	
transplant	recipients	and	HIV‐infected	patients,	 infections	are	a	major	concern	and	are	
associated	with	severe	morbidity	and	mortality.	Both	reactivation	and	primary	infection	
can	occur.	In	the	absence	of	vaccines	against	HCMV,	the	management	and	prevention	of	
infection	 relies	 on	 the	 three	 systemic	 drugs	 approved	 for	 CMV	 treatment,	 ganciclovir,	
foscarnet	 and	 cidofovir.	 Considering	 the	 extended	 treatment	 period	 required	 for	 the	
treatment	 in	 immunocompromised	patients,	 several	drawbacks	are	 limiting	 the	use	of	
these	drugs:	severe	acute	and	long‐term	toxicities,	and	a	shared	viral	target	with	the	risk	
of	 emergence	 of	 drug	 cross‐resistance.	 There	 is	 an	 urgent	 need	 for	 new	 therapeutic	
approaches	 with	 a	 good	 safety	 profile	 and	 an	 alternative	 mechanism	 of	 action	 that	
would	ideally	interfere	earlier	in	the	HCMV	replication	cycle.		
Statins	are	a	well‐tolerated	and	extensively	studied	group	of	cholesterol‐lowering	drugs,	
exhibiting	strong	anti‐inflammatory	and	immune‐modulatory	activities.	Antiviral	effects	
of	statins	have	been	reported	on	different	viruses	alone	or	in	combination	with	selective	
antiviral	 inhibitors	and	have	been	associated	with	cholesterol‐lowering	or	cholesterol‐
independent	mechanisms.	 So	 far,	 despite	 a	 large	 number	 of	 statins	 currently	 used	 in	
clinics,	little	is	known	about	the	potential	of	statins	against	HCMV.	The	goal	of	this	study	
was	 to	 investigate	 the	 in	 vitro	 anti‐CMV	activity	 of	 four	 statins	 (atorva‐,	 fluva‐,	 prava‐	
and	simvastatin)	in	human	aortic	endothelial	cells	(HAEC)	and	fibroblasts.		
Our	findings	demonstrate	that	all	statins	dose‐dependently	reduce	HCMV	titers	in	both	
cell	types.	Atorva‐,	fluva‐	and	simvastatin	showed	comparable	EC50	and	EC90,	within	a	
low	micromolar	range	in	HAEC,	whereas	pravastatin	exhibited	only	limited	effects.	The	
same	hierarchy	was	observed	 in	 fibroblasts,	 although	all	 statins	exhibited	 slightly	 less	
anti‐CMV	 potency.	 The	 reduction	 of	 HCMV	 titers	 did	 not	 result	 from	 an	 inhibition	 of	
HCMV	entry	or	an	activation	of	 the	 type	 I	 IFN	response,	but	 from	the	alteration	of	 the	
expression	of	several	viral	antigens.	Interestingly,	statins	treatment	not	only	blocked	the	
accumulation	of	immediate	early	antigens,	but	also	interferes	independently	with	early	
and	late	antigen	expression.		
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Despite	 our	 attempts,	 the	 key	 mediator	 of	 the	 anti‐CMV	 activity	 of	 statins	 was	 not	
identified.	 However,	 metabolite	 rescue	 experiments	 suggested	 an	 involvement	 of	 the	
non‐sterol	isoprenoid	arm	of	the	mevalonate	pathway	as	the	mode‐of‐action.	Anti‐CMV	
activity	 of	 all	 statins	 was	 almost	 completely	 abrogated	 by	 mevalonate	 and	 partially	
reversed	 by	 geranylgeranyl‐pyrophosphate,	 an	 isoprenoid	 intermediate,	 whereas	
cholesterol	failed	to	counteract	the	effects	of	statins.	In	an	attempt	to	evaluate	potential	
clinical	 benefits,	 we	 demonstrate	 an	 additive	 anti‐CMV	 activity	 of	 statins	 at	
therapeutically	 relevant	 concentrations.	 While,	 the	 antiviral	 activity	 of	 statins	 was	
comparable	 to	 ganciclovir,	 statins	 enhanced	 the	 anti‐CMV	 activity	 of	 low	 doses	 of	
ganciclovir	suggesting	a	potential	benefit	for	combination	therapy.	Finally,	statins	anti‐
CMV	activity	was	retained	in	a	ganciclovir‐resistant	HCMV	strain.		
In	conclusions,	 these	 findings	provide	new	insight	 into	 the	beneficial	effects	of	 statins,	
adding	 antiviral	 activity	 against	HCMV	 to	 their	 list	 of	 pleïotropic	 properties.	 Although	
the	in	vivo	anti‐CMV	activity	of	statins	might	be	limited	to	the	lipophilic	compounds,	this	
supports	 further	 clinical	 investigation	 of	 the	 beneficial	 use	 of	 statins,	 as	 part	 as	 a	
cholesterol‐lowering	 or	 anti‐inflammatory	 therapy,	 against	 HCMV	 infection.	 Special	
attention	should	be	taken	to	evaluate	statins	in	combined	therapy	for	the	management	
of	active	HCMV	disease	and	against	cross‐resistant	HCMV	strain.	Finally,	we	believe	this	
work	may	reveal	potential	targets	for	alternative	anti‐viral	therapies.	
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 Zusammenfassung	
Die	Neuinfektion	mit	humanen	Zytomegalieviren	(HZMV)	erfolgt	häufig	ohne	klinische	
Symptome,	 die	 Seroprävalenz	 steigt	 in	 der	 älteren	 Population	 bis	 gegen	 80%.	 Die	
lebenslange	Persistenz	ist	eines	der	entscheidenden	Merkmale	aller	Herpesviren.	Wird	
es	 notwendig,	 das	 Immunsystem	 medikamentös	 zu	 unterdrücken,	 wie	 nach	
Transplantation,	oder	kommt	es	im	Laufe	einer	HIV	Infektion	zu	einer	Immunschwäche,	
kann	 eine	 Reaktivierung	 oder	 eine	 Neuinfektion	 fatale	 Folgen	 haben.	 Eine	 baldige	
Impfung	ist	klinisch	nicht	zu	erwarten,	so	dass	die	Prävention	und	Behandlung	von	ZMV	
primär	 medikamentös	 durchgeführt	 wird.	 Drei	 Wirkstoffe	 sind	 dafür	 zugelassen:	
Ganciclovir,	 Foscarnet	 und	 Cidofovir.	 Ist	 eine	 längere	 Behandlung	 notwendig,	 sind	
relevante	 Nebenwirkungen	 kurz‐	 und	 langfristiger	 Art	 häufig,	 ebenso	 kann	 es	 zu	
Resistenzentwicklung	 kommen.	 Neue	 Therapieansätze	 sind	 nötig,	 die	 alternative	
antivirale	Mechanismen	benützen	und	ein	günstiges	Toxizitätsprofil	aufweisen.	
Statine	 gehören	 zu	 eine	 gut	 tolerierten	 und	 in	 der	 klinischen	 Anwendung	 mehrfach	
erprobten	Stoffklasse.	Neben	ihren	lipidsenkenden	Eigenschaften	sind	anti‐entzündliche	
und	 immune‐modulatorische	 Effekte	 beschrieben.	 Eine	 antivirale	 Potenz	wurde	 gegen	
verschiedene	 Viren	 nachgewiesen,	 entweder	 bei	 alleiniger	 Gabe	 oder	 in	 Kombination	
mit	 weiteren	 antiviralen	 Substanzen.	 Die	 Mechanismen	 beruhen	 teils	 auf	 den	
lipidsenkenden	 Eigenschaften	 der	 Statine,	 teils	 aber	 auch	 auf	 den	 oben	 erwähnten	
Zusatzeffekten.	
Die	 antiviralen	 Eigenschaften	 von	 Statinen	 gegen	 HZMV	 sind	 bis	 jetzt	 nur	 wenig	
erforscht.	Das	Ziel	dieser	Arbeit	war	es,	die	antivirale	Aktivität	gegen	HZMV	von	vier	in	
der	 Klinik	 gebräuchlichen	 Statinen	 nachzuweisen	 und	 die	Mechanismen	 aufzudecken.	
Wir	 benützten	 dafür	 Atorva‐,	 Fluva‐,	 Prava‐	 und	 Simvastatin,	 und	 entwickelten	 ein	
Endothelzellmodell	basierend	auf	humanen	Endothelzellen,	die	aus	der	Hauptschlagader	
stammen.	 Als	 Vergleich	 wurden	 Fibroblasten	 (Stützzellen	 des	 Bindegewebes)	
herangezogen.	
Unsere	 Resultate	 zeigten	 eine	 Dosis‐abhängige	 Reduktion	 der	 HZMV	 Replikation	 in	
beiden	 Zelltypen.	 In	 Endothelzellen	 wiesen	 Atorva‐,	 Fluva‐	 und	 Simvastatin	 eine	
vergleichbare	 Hemmung	 auf,	 während	 der	 antivirale	 Effekt	 von	 Pravastatin	 marginal	
war.	 Ein	 vergleichbares	 Resultat	 wurde	 auch	 in	 Fibroblasten	 gezeigt.	 Die	 Expression	
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viraler	Antigene	hingegen	war	deutlich	inhibiert,	und	zwar	war	nicht	nur	die	Produktion	
früher	 viraler	 Proteine,	 sondern	 auch	 diejenige	 späterer	 im	 Replikationszyklus	
auftretender	 Proteine.	 Die	Wirkung	 beruht	 nicht	 auf	 einem	 verminderten	 Eindringen	
von	HZMV	in	die	Zielzellen,	auch	ist	der	antivirale	Effekt	nicht	auf	eine	Aktivierung	einer	
zellspezifischen	antiviralen	Antwort	(z.b.	Interferon)	zurückzuführen.		
Es	war	 uns	nicht	möglich,	 einen	 einzelnen	 Schlüsselmechanismus	 für	 diesen	Effekt	 zu	
identifizieren.	 Statine	 hemmen	 verschiedene	 für	 den	 Zellhaushalt	 wichtige	 Vorgänge.	
Durch	 gezielte	 Zugabe	 verschiedener	 Produkte	 konnte	 der	 sog.	 Isoprenoid	 Arm	 des	
Mevalonat‐Stoffwechselpfades	als	derjenige	beschrieben	werden,	der	für	den	antiviralen	
Effekt	 verantwortlich	 ist.	 So	war	 die	 hemmende	Wirkung	 bei	 allen	 Statinen	 praktisch	
aufgehoben,	 wenn	 Mevalonate	 kompensatorisch	 dazugegeben	 wurde,	 und	 mit	
Geranylgeranyl‐pyrophosphat,	einer	weiteren	Substanz	dieses	Pfades,	konnte	der	Effekt	
der	 Statine	 teilweise	 antagonisiert	 werden.	 Cholesterin,	 auf	 der	 anderen	 Seite,	
beeinträchtigte	die	Wirkung	überhaupt	nicht.		
Die	 additive	 oder	mögliche	 synergistische	Wirkung	wurde	 in	 Kombinationsversuchen	
mit	 Ganciclovir	 getestet,	 in	 der	 Tat	 kam	 es	 zu	 einer	 verstärkten	 Wirkung	 bei	 der	
gemeinsamen	Gabe.	Statine	hatten	auch	bei	einem	gegen	Ganciclovir	resistenten	Stamm	
eine	antivirale	Wirkung.	
Zusammenfassend	erhellen	diese	Resultate	die	antivirale	Potenz	der	Statine	und	kreisen	
einen	 möglichen	 Mechanismus	 ein.	 Die	 antivirale	 Potenz	 muss	 zu	 den	 vielfältigen	
Eigenschaften	von	Statinen	dazugezählt	werden.	Die	weitere	Erforschung	der	Wirkung	
in	 klinischen	 Versuchen	 scheint	 gerechtfertigt,	 insbesondere	 bei	 gegenüber	 den	
herkömmlichen	 Therapien	 resistenten	 HZMV	 Stämmen.	 Neue	 Erkenntnisse	 der	
antiviralen	Mechanismen	können	neue	potentielle	antivirale	Ziele	aufzeigen.	
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 Introduction	
I. The	Human	Cytomegalovirus	
1. Historical	perspective	and	classification	
Clinical	manifestations	 of	 cytomegalovirus	 infection	were	 first	 noticed	 during	 the	 late	
19th	 century.	 The	 observation	 of	 typical	 cytomegalic	 cells	with	 an	 eccentrically	 nuclei	
containing	intranuclear	occlusions	with	an	halo	as	“protozoan	like”	cells	was	reported	in	
the	 kidney	 sections	 of	 a	 luetic	 stillborn	 by	 the	 german	 physician	 Ribbert	 [1]	 and	
described	based	on	similar	observation	by	Jesionek	and	Kiolemenoglou	in	1904	(Figure	
1).	 A	 viral	 etiology	 was	 later	 proposed	 for	 cytomegalic	 inclusion	 disease	 after	 the	
observation	 of	 such	 cells	 in	 patients	with	 herpes	 zoster	 and	 herpes	 genitalis	 [2].	 The	
high	 frequency	 of	 cytomegalovirus	 infection	 (present	 in	 12%	 of	 infants	 dying	 from	 a	
variety	of	causes)	was	further	reported,	as	well	as	the	variety	of	infected	organs	[3].		
The	identification	of	the	causal	agents	had	to	wait	for	the	improvement	of	cell	cultures	
techniques	 till	 1956/1957,	 when	 three	 groups	 independently	 identified	 a	 virus	 only	
growing	in	human	but	not	mouse	cells	[4],	from	an	infant	suspected	to	have	congenital	
toxoplasmosis	[5]	and	from	the	salivary	gland	and	the	kidney	of	two	different	patients	
[6].	This	virus	was	named	“Cytomegalovirus”	in	1960.		
Figure	1:	Intranuclear	inclusion	body	as	seen	in	the	year	1904.	
Reproduced	from	Jesionek	and	Kiolemenoglou,Muenchner	Med	Wochenschr,1904	[7]	
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The	 human	 cytomegalovirus	 (HCMV)	 belongs	 to	 the	Herpesviridae	 family	 regrouping	
more	 than	 200	 DNA	 viruses	 causing	 disease	 in	 animals,	 including	 humans	 [8].	 All	
herpesviruses	share	common	structures	and	features:		
‐ a	large	double‐stranded	linear	DNA	genomes	encoding	up	to	200	genes;	
‐ an	icosahedral	proteic	capsid	enclosed	in	a	matrix	of	viral	phosphoproteins	and	
mRNAs	called	the	tegument;		
‐ a	lipid	bilayer	envelope	containing	glycoproteins	complexes;	
‐ the	ability	to	undergo	lifelong	latent	infection	in	their	host;	
Herpesviruses	are	subdivided	into	three	subfamilies	(α‐,	β‐	and	γ‐	herpesvirinae),	based	
on	biological	criteria	such	as	host	range,	growths	kinetics,	cell	tropism	or	site	of	latency.	
HCMV,	 also	 known	 as	 human	 herpes	 virus‐5	 (HHV‐5),	 belongs	 to	 the	 β‐herpesvirinae,	
together	with	the	HHV‐6A	and	6B	and	HHV‐7.	They	are	characterized	by	large	genomes,	
a	 restricted	host	 range	and	a	 slow	replication	 cycle	of	up	 to	72	hpi	 in	 culture	and	are	
believed	to	establish	latency	in	lymphoid	cells.		
The	α‐herpesvirinae	 comprise	 three	human	viruses	 (herpes	 simplex	viruses	1/2,	HHV‐
1/2;	 varicella	 zoster	 virus,	 HHV‐3)	 that	 are	 characterized	 by	 i)	 smaller	 genomes	 as	
compared	 to	 β‐herpesvirinae,	 ii)	 a	 fast	 replication	 cycle	with	 release	 of	 progeny	 virus	
starting	already	after	8	hours	post	 infection	 (hpi),	 iii)	 a	 latency	established	 in	neuron.	
The	γ‐herpesvirinae	group	viruses	with	a	more	diverse	replication	rate	and	host	range,	
but	which	do	not	replicate	in	vitro	in	lymphoblastoid	cells.	Two	major	human	pathogens,	
the	Epstein‐Barr	virus	 (EBV,	HHV‐4)	and	 the	Kaposi's	 sarcoma‐associated	herpesvirus	
(KSHV,	HHV‐8)	belong	to	this	subfamily.		
2. HCMV	structure	and	replication	cycle	
Contrary	 to	 the	restricted	host	range	attributed	to	herpesviruses,	a	broad	spectrum	of	
cell	 types	 is	 permissive	 for	 HCMV	 in	 vivo	 and	 in	 vitro.	 With	 the	 exception	 of	 cells	 of	
lymphoid	 origin	 most	 cells	 types	 are	 invaded	 by	 viral	 particles	 and	 express	 at	 least	
immediate	early	 (IE)	antigens.	However,	 full	productive	 infection	preferentially	occurs	
in	 terminally	 differentiated	 cells	 including	 endothelial	 cells	 (EC)	 and	 fibroblasts,	 and	
results	 in	 the	release	of	 infectious	progenies	 [9].	The	HCMV	infectious	particles	are	an	
assembly	 of	 three	 major	 layers:	 a	 nucleocapsid	 containing	 the	 double	 stranded	 DNA	
genome,	an	amourphous	proteinaceous	layer	encompassing	the	nucleocapsid	known	as	
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the	 tegument,	 a	 trilaminar	 lipid	 envelope	 of	 an	 overall	 size	 of	 approximately	 230	 nm	
(Figure	2).	
	
Figure	2:	The	architecture	of	HCMV	particles	
Reproduced	from	Human	Cytomegalovirus;	International	Medical	Press,	2007[10].	
2.1 HCMV	entry	into	host	cell	
HCMV	entry	into	human	cells	is	a	sequential	process	requiring	the	interaction	between	
multiple	 cellular	and	viral	 components	 to	allow	 the	adsorption	and	 the	penetration	of	
the	viral	 capsid	 into	 the	cytoplasm.	The	many	HCMV‐permissive	cell	 types	suggest	 the	
use	of	receptor(s)	common	to	most	cells.		
The	 initial	 interaction	occurs	with	HCMV	membrane‐anchored	glycoprotein	complexes	
(gM/gN	and	gB)	binding	to	the	cell	surface	heparin	sulphate	proteoglycans,	allowing	the	
transient	 tether	 of	 the	 virions.	 Stable	 docking	 of	 the	 viral	 particles	 and	 entry	 through	
cellular	trans‐membrane	protein	receptors	is	then	mediated	by	the	glycoproteins	gB	and	
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gH/gL/gO	complexes	[11].	Different	entry	pathways	have	been	identified	depending	on	
the	cell	type,	via	endocytosis	in	a	pH‐dependent	manner	(for	EC)	or	by	a	pH‐insensitive	
membrane	 fusion	(fibroblasts)	 [12,	13].	Both	entry	pathways	 involve	common	cellular	
receptors;	epidermal	growth	factor	receptor	(EGFR),	v‐β3	or	β1	integrins	act	as	HCMV	
receptor	or	co‐receptors	[14‐16].	The	fusion	of	the	envelope,	either	with	the	endocytic	
or	cytoplasmic	membrane,	will	allow	the	release	of	the	nucleocapsid	into	the	cytoplasm	
(Figure	 3).	 The	 binding	 and	 fusion	 of	 the	 viral	 particles	with	 the	 host	 cell	membrane	
triggers	 significant	 induction	 of	 cellular	 pathway	 such	 as	 TLR‐2	 or	 the	 activation	 of	
cellular	transcription	factors	essential	for	the	initiation	of	HCMV	replication.	
2.2 Initiation	of	the	viral	gene	expression	and	DNA	replication	
Teguments	 proteins	 are	 fully	 formed	 and	 active	 proteins	 mediating	 all	 events	 from	
release	of	the	viral	nucleocapsid	within	the	cytoplasm	to	the	initiation	of	the	viral	gene	
expression.	The	nucleocapsid	is	believed	to	translocate	through	the	cytoplasm	along	the	
microtubules	network,	using	 the	 intracellular	 transport	machinery	 [17].	The	 tegument	
phosphoprotein	pp150	that	is	tightly	associated	with	the	capsid	during	this	transit,	play	
a	crucial	role	within	this	process	and	is	considered	essential	for	lytic	replication	in	vitro	
[18].	The	complex	formed	by	two	others	tegument	proteins	pUL47/48	together	with	the	
major	capsid	protein,	seems	also	to	be	involved	in	the	transport	of	the	capsid	and/or	the	
injection	of	the	viral	DNA	into	the	nucleus	through	the	nuclear	pore	complex.		
HCMV	 contains	 a	 large	 (236	 kb)	 and	 complex	 genome,	 encoding	 over	 200	 predicted	
open	 reading	 frames	 (ORF),	 thus	 having	 the	 largest	 coding	 capacity	 among	
herpesviruses	 [19].	 This	 linear	 double	 stranded	 DNA	 genome	 is	 organized	 in	 two	
domains,	 the	unique	 long	and	short	segment	(UL	and	US),	each	one	flanked	by	a	repeat	
sequence.	 HCMV	 genes	 nomenclature	 refers	 to	 the	 localization	 in	 the	 genome	 and	 is	
composed	of	the	domain	(UL	or	US)	and	of	the	serial	number	of	the	ORF	starting	from	
the	 5’	 end.	 The	 genes	 products	 are	 referred	 by	 a	 “p”	 in	 front	 of	 the	 gene	 name	 (e.g.	
pUL44)	 except	 in	 the	 case	 of	 phosphoprotein,	where	 the	 number	 correspond	 to	 their	
molecular	weight	(e.g.	pp65).	The	genome	also	contains	various	transcriptional	control	
regions	that	direct	viral	gene	expression,	DNA	replication,	packaging	and	transcription.	
The	replication,	 typical	of	herpesviruses,	 is	a	complex	 temporally	 regulated	cascade	of	
events,	with	three	families	of	genes	being	subsequently	expressed:	the	immediate	early	
(IE)	 genes	within	 the	 first	 hours	 after	 the	 beginning	 of	 the	 infection,	 followed	 by	 the	
early	(E)	genes	and	the	late	(L)	genes	at	last.		
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Figure	3:	Complete	replication	cycle	of	the	human	cytomegalovirus	
Reproduced	from	T.C.	Mettenleiter,	2004	[20]	
	
The	transcription	of	the	IE	genes	locus	begin	shortly	after	release	of	the	viral	DNA	into	
the	nucleus,	under	the	control	of	the	major	immediate	early	enhancer‐promoter	(MIEP),	
without	the	synthesis	of	de	novo	viral	protein	[21].	This	region	is	transactivated	by	the	
tegument	 proteins	 pUL69	 and	 pUL82	 that	 accumulates	 into	 the	 nucleus	 but	 contains	
also	multiple	binding	sites	for	cellular	transcription	factors	such	as	NF‐κB.	IE1	and	IE2	
are	 the	 two	 main	 proteins	 expressed	 after	 the	 differential	 splicing	 of	 the	 major	 IE	
transcript.	They	act	synergistically	to	activate	the	expression	of	the	viral	E	proteins,	and	
autoregulate	the	MIEP	in	an	antagonistic	manner.	IE1	(IE72,	pUL123),	the	first	of	these	
two	 nuclear	 phosphoproteins	 to	 be	 expressed,	 accumulates	within	 the	 first	 6	 hpi	 and	
appears	to	have	multiple	roles.	IE1	disperses	the	nuclear	domain	10	to	facilitate	the	CMV	
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genome	transcription	and	activate	the	MIEP	promoter.	IE1	is	also	a	major	antagonist	of	
the	 cellular	 innate	 immune	 response,	 blocking	 the	 signal	 transduction	 of	 the	 type	 1	
interferon	 (IFN)	 response	 [22].	 Contrary	 to	 IE1,	which	 is	 not	 essential	 for	 productive	
replication	 but	 appears	 to	 be	 necessary	 for	 replicative	 success	 at	 low	 multiplicity	 of	
infection	 (MOI),	 IE2	 (IE86,	 pUL122)	 is	 crucial	 for	 the	 lytic	 replicative	 cycle.	 IE2	
negatively	 autoregulates	 its	 own	 expression	 through	 the	 MIEP	 	 and	 acts	 as	 the	main	
transactivator	of	the	viral	E/L	promoter.	In	addition,	IE2	interacts	with	several	cellular	
promoters	to	induce	the	cell	cycle	progression	from	G0/G1	to	G1/S	phase	and	to	block	
the	 G2/M	 transition	 in	 order	 to	 create	 a	 cellular	 environment	 favorable	 for	 viral	
replication	[23].		
The	onset	of	the	viral	DNA	synthesis	befalls	at	around	24	hpi,	after	the	expression	of	the	
E	 gene	 products	 requires	 for	HCMV	 core	 replication	machinery.	 Eleven	 proteins	 have	
been	identified	as	essential	for	the	viral	DNA	replication	(Figure	3).	Once	released	in	the	
nucleus,	the	viral	DNA	circularizes	thanks	to	an	unpaired	nucleotide	at	both	the	3’	and	5’	
ends	 and	 will	 be	 used	 as	 a	 template	 for	 the	 production	 of	 a	 concatameric	 DNA,	 a	
mechanism	 shared	with	 other	 herpesviruses	 [24].	 The	 unique	 origin	 of	 replication	 of	
HCMV	 genome,	 oriLyt,	 directs	 the	 initiation	 of	 the	 	 DNA	 replication	 [25],	 where	 the	
helicase‐primase	complex	 (pUL70,	pUL105	and	pUL102)	unwinds	 the	ds‐DNA	genome	
at	 the	5’	end	to	allow	the	elongation	of	 the	viral	genome	by	 the	viral	DNA	polymerase	
pUL54,	 using	 the	 free	 3’‐end	 as	 primer.	 pUL54	 activity	 depends	 upon	 the	 association	
with	pUL44	(pp52,	ICP36),	the	DNA	polymerase	processivity	factor	which	prevents	the	
dissociation	of	the	DNA	polymerase	from	the	DNA	template	and	the	single	stranded	DNA	
binding	protein	pUL57,	which	prevents	 in	 the	meanwhile	 the	 re‐annealing	of	 the	DNA	
strands.	 Further	 proteins	 play	 a	 role	 in	 DNA	 replication:	 IRS1/TRS1	 acts	 as	
transactivator,	pUL112/113	ensures	 the	 recruitment	of	 the	 replication	proteins	 to	 the	
nuclear	 sites	 of	 DNA	 synthesis,	 pUL36	 and	 pUL37	 prevents	 the	 cell	 apoptosis	 in	
responses	to	HCMV	infection	to	ensure	the	complete	replication	cycle.		
Prior	to	encapsidation,	the	cleavage	of	the	concatameric	DNA	into	unit	genome	lengths	is	
performed	by	the	terminase	complex	(pUL56	and	pUL89).	
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2.3 Morphogenesis	of	the	virions	
The	 structural	 components	 of	 the	 viral	 particles,	 e.g.	 capsomeres,	 tegument	 and	
glycoproteins,	are	encoded	by	the	L	family	of	genes,	whose	expression	occurs	after	the	
onset	of	the	viral	DNA	replication.		
		The	 capsid	 assembly	 and	maturation	 process	 is	 tightly	 coordinated	 by	 the	 assembly	
protein	 precursor	 (pAP,	 pUL80.5)	 and	 the	 maturational	 protease	 precursor	 (pPR,	
pUL80a),	 later	 eliminated	 from	 the	matured	particles.	 In	 the	 cytoplasm,	 pAP	 interacts	
with	 the	 major	 capsid	 protein	 (MCP,	 pUL86)	 to	 form	 the	 protocapsomers.	 The	 other	
integral	subunit	of	the	capsid	shell	is	formed	by	two	copies	of	the	minor	capsid	protein	
(mCP,	pUL85)	interacting	with	the	mCP‐binding	protein	(mCBP,	pUL46)	to	constitute	a	
triplex.	After	translocation	into	the	nucleus,	the	two	types	of	oligomers	coalesce	together	
with	the	portal‐protein	complex	(pUL104),	a	ring	shaped	structure	that	forms	a	channel	
for	 the	viral	DNA	to	enter	and	 leave	the	capsid	[26].	The	smallest	capsid	protein	(SCP,	
pUL48/49),	an	essential	protein	for	the	virion	infectivity,	binds	to	the	external	surface	of	
the	procapsid	[27,	28].	During	the	maturation	process,	the	internal	scaffolding	proteins	
(pPR	 and	 pAP)	 are	 eliminated	 and	 the	 newly	 replicated	DNA	 is	 incorporated	 into	 the	
capsid.	The	mature	viral	capsid	is	an	icosahedral	scaffold	structure,	similar	in	size	(≈110	
nm)	and	shape	to	HSV,	organized	in	162	capsomeres	and	320	triplexes	located	between	
the	capsomeres	(Figure	2).		
The	 nucleocapsid	 exits	 the	 nucleus	 via	 an	 envelopment/	 de‐envelopment	 process	
through	 the	 nuclear	 cisterna	 (Figure	 3).	 The	 process	 of	 assembly	 of	 the	 tegument	 is	
poorly	 understood	 and	 it	 is	 not	 clear	 whether	 it	 only	 starts	 after	 the	 egress	 of	 the	
nucleus	or	 if	 some	proteins	 already	accumulate	 around	 the	nucleocapsid	while	 still	 in	
the	nucleus.	The	 final	envelopment	of	 the	 fully	 tegumented	capsids	occurs	by	budding	
into	the	trans‐golgi	network‐derived	vesicles	where	viral	glycoproteins	accumulate.	The	
vesicle	containing	the	enveloped	virion	is	transported	to	the	plasma	membrane	where	it	
fuse	to	release	the	mature	virion	from	the	infected	cells	to	the	extracellular	space.	
3. Epidemiology,	pathogenesis	and	management	of	CMV	
disease	
CMV	 disease	 is	 the	 result	 from	 a	 complex	 interplay	 between	 the	 consequences	 of	 the	
lytic	 viral	 replication,	 including	 the	 resulting	 inflammation,	 and	 the	 immunological	
status	 of	 the	 host.	 Primary	 CMV	 infection	 in	 immunocompetent	 host	 is	 sometimes	
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accompanied	 by	 clinical	 symptoms,	 but	 often	 is	 a	 silent	 infection.	 In	
immunocompromised	 host	 HCMV	 infections	 are	 a	 major	 cause	 of	 morbidity	 and	
mortality.	 In	 particular,	 CMV	 disease	 resulting	 from	 a	 primary	 infection	 in	 subject	
without	prior	 specific	 immunity	 against	HCMV	may	produce	a	more	 severe	disease	 as	
opposed	to	infection	resulting	from	reactivation	of	the	latent	infection	or	reinfection	by	
a	new	virus	strain.	HCMV	infection	has	also	been	associated	with	chronic	disease,	in	both	
immunocompromised	and	immunocompetent	hosts.	
3.1 Mode	of	transmission	and	epidemiology	
HCMV	 is	 a	 ubiquitous,	 opportunistic	 but	 usually	 asymptomatic	 pathogen	 in	 the	whole	
population	 throughout	 the	world.	 The	 seroprevalence	 is	 inversely	 correlated	with	 the	
socio‐economic	 conditions	 and	 reaches	 nearly	 100%	 in	 children	 and	 adults	 from	
undeveloped	countries	and	is	estimated	to	be	between	40	and	60%	in	adults	of	Northern	
America,	Europe	or	Australia	[29].		
Although	 HCMV	 is	 a	 highly	 labile	 pathogen,	 it	 is	 readily	 transmitted	 during	 primary	
infection,	reactivation	or	reinfection,	by	direct	or	indirect	person‐to‐person	contact.	The	
first	main	period	for	natural	transmission	occurs	during	the	perinatal	period	(0‐2	years)	
and	 the	 young	 childhood	 [30].	 Intrauterine	 infection	 in	 the	 United	 State	 is	 estimated	
between	0.1	and	1%	of	all	live	births	(over	40,000	a	year).	In	addition,	horizontal	mode	
of	 transmission	 to	 neonates	 includes	 contact	with	 infectious	 genital	 secretions	 during	
birth	(virus	shed	from	the	uterine	cervix)	and	contamination	via	breast	milk	or	saliva	of	
the	mother.	A	major	route	for	HCMV	transmission	results	from	young	children	attending	
to	 group	 cares	 since	 HCMV	 infection	 during	 early	 years	 is	 associated	with	 prolonged	
excretion	of	infectious	virus	into	body	fluid	(saliva,	urine)	persisting	for	years.	This	plays	
a	a	major	role	for	HCMV	transmission	to	the	parents.		
The	second	main	period	of	infection	arise	with	sexual	activity	in	adolescent	and	adults.	
HCMV	sexual	transmission	follows	close	contact	of	oral	or	genital	mucosa,	HCMV	being	
shredded	 by	 both	 male	 and	 female	 genital	 tracts.	 Seroprevalence	 reach	 40%	 by	
adolescence	and	the	infectious	rate	is	estimated	to	increase	by	around	1%	per	annum.
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3.2 CMV	infections	in	normal	hosts	and	aspects	of	latency	
Although	 the	 primary	 infection	 is	 not	 associated	 with	 clinical	 symptoms	 in	 the	 large	
majority	of	normal	host,	it	rarely	manifests	as	nonspecific	mononucleosis‐like	syndrome	
with	 fever,	 fatigue,	 atypical	 lymphocytes	 and	 evidence	 of	mild	 hepatocellular	 damage	
(Table	1)	[31,	32].		
The	course	of	HCMV	dissemination	usually	begins	at	the	mucosal	epithelium	site	of	the	
inoculation	 where	 the	 virus	 will	 easily	 replicate	 locally.	 Cell‐to‐cell	 transmission	 and	
lytic	 replication	 results	 in	 primary	 viremia.	 The	 virus	 further	 spreads	 to	 the	 main	
visceral	sites	of	amplification	e.g.	the	liver,	lung	and	spleen	[33].	Due	to	a	broad	cellular	
tropism,	 HCMV	 can	 infect	 almost	 every	 organ.	 HCMV	 dissemination	 is	 believed	 to	 be	
highly	 cell‐associated,	with	 EC	 playing	 a	major	 role	 in	 this	 process	 [34].	 A	 ubiquitous	
distribution	 of	 HCMV‐infected	 EC	 have	 been	 detected	 in	 both	 microvascular	 and	
macrovascular	 vessels	 of	 various	 organs	 and	 have	 been	 shown	 to	 support	 productive	
lytic	 replication	 [9].	 The	 expression	 of	 pro‐inflammatory	mediators	 (IL‐8	 and	 IL‐6)	 in	
response	to	the	endothelial	layer	infection	will	allow	the	recruitment	of	neutrophils	and	
monocytes	 [35‐38].	 Both	 cell	 types	 will	 uptake	 virus	 particles	 during	 transmigration	
through	the	EC	layer	and	transmit	the	infection	into	tissues.	Whereas	neutrophils	do	not	
support	full	HCMV	replication	and	only	passively	transport	infectious	particles	[39,	40],	
monocytes	 support	 the	 full	 replicative	 cycle	 once	 differentiated	 into	 tissue‐resident	
macrophages	and	can	release	progenies	into	the	corresponding	organ	[41].	In	addition,	
neutrophils	and	monocytes	may	play	a	role	in	the	establishment	of	latency.	
Indeed,	 like	 all	 herpesvirus,	 HCMV	 establishes	 a	 lifelong	 latent	 infection	 in	 its	 host.	
Important	mechanisms	of	latency	remain	to	be	elucidated:	the	exact	nature	of	the	latent	
state,	 the	process	of	 induction	of	 latency	or	 the	reactivation	 from	the	 latent	state.	Any	
organ	from	a	seropositive	donor	was	presume	to	vehicle	latent	CMV	infection	after	the	
seroconversion	 of	 seronegative	 recipients	 of	 a	 kidney,	 heart,	 liver	 or	 lung	 graft	 from	
seropositive	donors,	despite	the	absence	of	any	replicating	virus	found	within	culture	of	
the	graft	biopsy	[42].	In	1997,	Hendrix	et	al.	found	HCMV	DNA	was	widely	distributed	in	
organs	of	healthy	subjects,	confirming	the	hypothesis.		
HCMV	infection	has	been	reported	to	highly	impact	a	variety	of	EC	functions	in	vitro	and	
in	vivo.	Data	 from	 rodent	 studies	 emphasized	 an	 active	 role	 of	 CMV	 in	 vascular	 injury	
most	 likely	 through	 the	 induction	 of	 inflammation,	 however	 the	 exact	 mechanisms	
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remain	 to	 be	 defined	 [43,	 44].	 A	 study	 from	 Khoretonenko	 et	 al.,	 performed	 in	mice,	
showed	 that	 persistent	 CMV	 infection	 resulted	 in	 impaired	 endothelium	 function	 and	
mild	 inflammation	 in	 venules	 [45].	 Moreover,	 in	 vitro	 infection	 of	 human	 EC	 with	 a	
clinical	 isolates	 or	 laboratory	 strain	of	HCMV	elicited	 a	potent	 inflammatory	 response	
characterized	by	the	alteration	of	adhesion	molecule	expression	or	the	up‐regulation	of	
pro‐inflammatory	 cytokines	 [46‐48].	 Consistently,	 a	 growing	number	of	 epidemiologic	
studies	 have	 implicated	 HCMV	 in	 the	 pathogenesis	 of	 cardiovascular	 diseases	 (CVD),	
such	 as	 atherosclerosis	 or	 coronary	 artery	 disease	 [49‐52].	 HCMV‐seropositive	
individuals	 without	 previous	 history	 of	 CVD	 present	 endothelial	 dysfunction	 and	 an	
increased	atherosclerotic	burden	[53].		
3.3 CMV	disease	in	immunocompromised	hosts	
Neonates,	HIV‐infected	patients	and	allografts	recipients	represent	 the	three	groups	of	
immunocompromised	patients	of	considerable	medical	importance	associated	with	end‐
organ	disease.	
3.3.1 Congenital	and	neonatal	infection	
Congenital	 and	 neonatal	 infection	 with	 HCMV	 not	 only	 represents	 one	 of	 the	 leading	
causes	of	 cognitive	disorders	 in	 children,	but	 is	 also	 a	major	 cause	of	 acute	morbidity	
and	mortality	in	neonates.	
Mother	 to	 newborn	 HCMV	 transmission	 proceeds	 through	 three	 possible	 routes:	
transplacental	resulting	in	congenital	infection,	perinatal	or	breastfeeding.	These	modes	
of	 vertical	 transmission	 correspond	 to	 10	 to	 50%	 of	 infants	 with	 HCMV	 infection,	 in	
most	 cases	 asymptomatic.	 It	 is	 however	 to	 be	 noted	 that	 theses	 perinatally	 infected	
infants	will	persistently	excrete	large	amounts	of	virus	(up	to	4‐5	logs	per	ml	of	urine),	
sometimes	for	years,	playing	a	major	role	as	reservoirs	for	the	spreading	of	CMV	in	the	
population.	HCMV	transmission	to	the	fetus	mainly	occurs	in	case	of	maternal	primary	
infection	 during	 pregnancy	 (transmission	 rate	 of	 20	 to	 50%)	 as	 compared	 to	women	
with	preconceptional	immunity	(0.1‐2.0%).	Nevertheless,	secondary	maternal	infection	
(reactivation	or	reinfection)	 is	associated	with	a	much	higher	 incidence	of	 long‐lasting	
damage	 following	 congenital	 infection,	 although	 only	 5%	 of	 infected	 infants	 show	
clinical	symptoms	at	birth	[33].		
Intrauterine	 transmission	 is	 traditionally	 thought	 to	 rise	 from	a	viremic	 spread	 to	 the	
uterine‐placental	 junction,	 ECs	 and	 the	 placental	 trophoblasts	 offering	 ideal	
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compartments	 for	 viral	 replication	 and	 entry	 of	 the	 virus	 in	 the	 fetal	 blood	 system.	
Damage	 to	 the	 fetus	 might	 occur	 in	 a	 variety	 of	 organ	 systems	 presumably	 by	 lytic	
replication	 (hepatobiliary	 system,	 CNS,	 lungs,	 hematopoietic	 system)	 [54].	 The	
gestational	 age	 of	 the	 fetus	 at	 the	 time	 of	 infection	 seems	 to	 be	 of	 great	 importance	
regarding	the	extent	and	the	severity	of	the	disease	(Table	1)	and	mortality	to	issue	in	
around	10%	of	symptomatic	newborns.	Long‐lasting	sequel	appears	to	results	mainly	in	
organ	system	with	low	regenerative	capacity,	brain	damage	and	hearing	loss	being	the	
most	common	manifestations	occurring	in	5%	to	20%	of	cases.	
	
Population	 Diseases	associated					with	acute	infection	
Diseases	associated		
				with	chronic	infection	
Immunocompetent	 Asymptomatic	infection
		mononucleosis‐like	illness	
Atherosclerotic	vascular	disease;
		inflammatory	bowel	disease,				
		periodontal	disease,		
		rheumatologic	disorders	
Immunocompromised	 	
			Fetal	and	newborn	infants	
			(congenital	infection)	
Asymptomatic	infection	(90%)	
		10%	can	have	hepatitis	
		retinitis,	thrombocytopenia,		
		neurologic	disease	
Hearing	loss	(5%‐15%);	
		neuron‐development			
		abnormalities	
			Allograft	recipients	 Fever,	
		decreased	bone	marrow	
function	
		hepatitis,	pneumonitis		
		bacterial	superinfections	
Transplant	Vascular	Sclerosis	
		interstitial	tubulosclerosis	(renal			
		allografts);	loss	of	bile	ducts		
		(liver	allografts)		
		chronic	graft	rejection	and	graft		
		loss	
			Immunodeficiency			
			syndromes	
			(acquired	and	inherited)	
Retinitis,	
			gastrointestinal	disease	
			(esophagitis,	colitis),	
			encephalitis	
	
			Aged	 Unknown Immune	senescence	
		with	potential	decrease		
		in	immune	responsiveness	
Table	1:	Clinical	manifestations	of	HCMV	infection	
Adapted	from	W.	Britt,	Manifestations	of	HCMV	infection;	
Current	Topics	in	Microbiology	and	Immunology	325,	2008	[33]		
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3.3.2 Patients	infected	with	HIV	
HCMV	 is	 the	 most	 common	 and	 severe	 viral	 opportunistic	 infection	 in	 HIV	 infected	
patients.	CMV	disease	is	classified	as	an	AIDS‐defining	illness	according	to	the	Center	for	
Disease	Control	and	Prevention	[33].	
Large	 prospective	 studies	 have	 associated	 increasing	 HCMV	 viremia	 as	 a	 strong	
predictor	 of	 the	 future	 development	 of	 CMV	 disease	 and	 death,	 independently	 of	 the	
CD4+	cell	count	 [55].	Over	90%	of	HIV	patients	are	seropositive	 for	HCMV.	The	 loss	of	
adaptive	immune	responses	in	the	late	stage	of	the	disease	increases	the	risk	for	acute	
HCMV	 infection	 and	 subsequent	 end‐organ	 disease	 secondary	 to	 reactivation,	
uncontrolled	 virus	 replication	 and	 widespread	 viral	 dissemination.	 CMV	 disease	 was	
reported	in	20	to	40%	of	AIDS	patients	[56].		
The	clinical	manifestations	of	CMV	disease	and	the	organs	 involved	are	function	of	the	
severity	of	the	immunological	deficiency	(Table	1).	The	most	common	and	characteristic	
manifestations	are	CMV	retinitis	(80%	of	the	patients)	that	can	lead	to	loss	of	sight,	and	
CMV	 colitis	 resulting	 from	 infection	 of	 the	 gastrointestinal	 tract	 (15%	 of	 the	
patients)[57].	 The	 use	 of	 antiviral	 therapy,	 either	 local	 or	 systemic,	 with	 an	 effective	
inhibition	of	the	virus	replication	can	halt	disease	progression	and	lead	to	the	resolution	
of	 the	 acute	 symptoms	 of	 the	 disease.	 The	 introduction	 of	 highly	 active	 antiretroviral	
therapy	(HAART)	resulting	in	the	immune	reconstitution	and	the	rise	of	CD4+	count	has	
strongly	decreased	the	occurrence	of	both	CMV	retinitis	and	colitis	[58‐60].	An	unusual	
characteristic	of	CMV	disease	in	adults	is	the	involvement	of	the	central	nervous	system	
giving	 rise	 to	 CMV	polyradiculopathy	 and	CMV	encephalitis.	 These	pathologies	 induce	
some	cognitive	 and	motor	disturbances	due	 to	 infection	of	 the	 cerebrospinal	 fluids	or	
the	acute	inflammation	of	the	brain	and	were	often	fatal.	
3.3.3 CMV	disease	in	allografts	recipients	
HCMV	 is	 the	 single	 most	 important	 cause	 of	 infectious	 disease	 after	 solid	 organ	
transplantation	 (SOT).	 Over	 75%	 of	 SOT	 recipients	 have	 laboratory	 and/or	 clinical	
evidence	of	CMV	replication	during	the	1st	year	post‐transplant	[61].	CMV	infection	has	
been	associated	with	increased	mortality	and	morbidity	after	transplantation	and	with	
diminished	graft	survival	[62,	63].	The	incidence	of	CMV	disease	varies	according	to	the	
organ	 transplanted,	 the	 serostatus	 of	 the	 donor	 and	 the	 recipient	 and	 the	 level	 of	
immunosuppression.	
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HCMV	 infection	 in	 SOT	 recipients	 has	 been	 strongly	 correlated	 with	 reactivation‐
reinfection	 from	 a	 latent	 infection.	 Thus	 the	 seropositivity	 of	 the	 organ	 donors	 and	
recipients	are	used	to	define	the	risk	of	developing	HCMV	infection/disease	in	the	post‐
transplant	 period.	 CMV	 seronegative	 patients	 receiving	 an	 organ	 from	 a	 CMV	
seropositive	donor,	D+/R‐	mismatch,	have	the	greatest	risk	for	infection:	the	incidence	of	
symptomatic	 disease	 reaches	 70%,	 with	 severe	 infection	 as	 a	 result	 of	 uncontrolled	
virus	replication	particular	in	the	early	post‐transplant	period	[64].	These	patients	have	
about	 a	 two‐	 to	 three‐fold	 higher	 incidence	 of	 late	 disease	 following	 antiviral	
prophylaxis	 as	 compared	 to	 the	other	groups	 [65‐67].	The	 combinations	D+/R+	and	D‐
/R+	 are	 considered	 as	 intermediate	 risks	 for	 severe	 disease	 (10‐30%)	 suggesting	 a	
predominant	role	of	the	pre‐existing	immunity	in	the	control	of	HCMV	replication.	The	
nature	of	 immunosuppressive	regimen	will	have	a	major	 impact	 in	 these	groups	since	
the	MHC‐restricted	 virus‐specific	 cytotoxic	T	 cells	 are	 key	 players	 in	 the	 host	 defense	
against	CMV[64,	68].	D‐/R‐	have	a	relative	low	risk	if	CMV	infection	(5%).	In	the	case	of	
bone	marrow	transplantation,	it	is	to	be	noted	that	the	higher	risk	of	infection	occurs	in	
D‐/R+	especially	when	T‐cell	depletion	is	used.		
	
Figure	4:	Overview	of	direct	and	indirect	effects	of	CMV	infection	in	allograft	
recipients.	
Reproduced	from	Fishman	et	al.,	Clin	Transplant,	2007[69]	
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HCMV	replication	or	seroconversion	commonly	occurs	within	3	months	post‐transplant	
in	 the	 absence	 of	 prophylaxis,	 and	 must	 not	 necessarily	 results	 in	 clinical	 symptoms	
(Table	 1).	 The	 most	 common	 manifestation,	 the	 “CMV	 syndrome”,	 is	 similar	 to	 any	
systemic	 viral	 infection	 and	 characterized	 by	 unexplained	 fever,	 flu‐like	 or	
mononucleosis‐like	 symptoms	 (including	 a	 5‐10%	 atypical	 lymphocytosis).	 Tissue‐
invasive	 disease	 occurs	 with	 a	 predilection	 for	 the	 greatest	 inflammatory	 pathology	
within	the	transplanted	organ	(hepatitis,	pneumocystis	and	myocarditis)	and	can	results	
in	 the	destruction	of	 the	 infected	tissue	either	directly	because	of	viral	replication	and	
cell	lysis	or	as	consequences	of	the	host	immune	responses	[61,	70].	
Aside	 from	the	direct	effects	of	 infection,	HCMV	 is	associated	with	 “indirect	effects”	 in	
SOT	recipients,	mainly	related	to	 immune	responses	 in	the	setting	of	 longer	periods	of	
low‐level	viral	replication	(Figure	4).	HCMV	infection	strongly	contributes	to	a	general	
non‐specific	immunosuppressive	syndrome	in	transplant	recipients,	making	the	patients	
more	 susceptible	 to	 others	 opportunistic	 pathogens	 [64].	 HCMV	 in	 associated	 with	
leukopenia	(decreased	number	of	polymorphonuclear	leukocytes),	a	decreased	ratio	of	
T	 helper/	 T	 cytotoxic	 ratio	 and	 an	 impaired	 cell‐mediated	 immunity.	 Opportunistic	
infections,	 such	 as	 bacterial	 infections	 or	 accelerated	 hepatitis	 C	 after	 liver	
transplantation	have	been	 associated	 to	 SOT	 recipients	with	HCMV	 infection	 [71].	 Co‐
infection	with	EBV	increased	by	seven‐	to	ten‐fold	the	incidence	of	EBV‐associated	post‐
transplant	lympho‐proliferative	disease	[72,	73].	
Although	 already	 hypothesized	 in	 1970,	 a	 clear	 association	 between	 HCMV	 infection,	
allograft	injury	and	rejection	was	only	recently	demonstrated	with	clinical	studies	using	
prophylaxis	 treatment.	 Renal	 transplants	 with	 D+/R‐	 mismatch	 receiving	 anti‐CMV	
prophylaxis	 showed	 a	 50%	 reduction	 in	 organ	 rejection	 compared	 to	 placebo	 [74].	
Similarly,	anti‐CMV	prophylaxis	improved	liver	transplant	recipient’s	survival	[75].	One	
clear	manifestation	of	CMV‐mediated	allograft	 injury	was	 reported	 in	heart	 transplant	
recipients	 where	 both	 acute	 rejection	 and	 accelerated	 coronary	 atherosclerosis	 were	
identified	 in	 patients	 with	 symptomatic	 and	 asymptomatic	 CMV	 infection,	 coronary	
artery	disease	being	a	major	cause	of	long‐term	mortality	following	transplantation	[76].	
The	 exact	 mechanism	 of	 CMV‐induced	 allograft	 damage	 is	 unknown	 but	 is	 strongly	
believed	to	involve	inflammatory	changes,	largely	extend	in	presence	of	CMV	in	all	forms	
of	 organs	 transplantation.	 Other	 factors	 such	 as	 ischemia	 reperfusion	 injury	might	 be	
involved	in	these	processes.		
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4. Management	of	HCMV	infection	
4.1 Prevention	and	treatment	of	CMV	disease	in	transplant	
recipients	
Different	 strategies	 are	 used	 in	 the	 transplant	 setting	 according	 to	 the	 group	 of	 risk	
aiming	to	reduce	and	maintain	HMCV	replication	below	a	critical	threshold	and	limit	the	
chances	of	CMV	disease	development.	Three	strategies	of	administration	are	currently	
used:	prophylactic,	pre‐emptive	and	therapeutic.		
Universal	 prophylaxis	 consists	 in	 the	 administration	 of	 drug	 to	 an	 entire	 population,	
before	any	sign	of	active	replication	of	 the	virus.	Prophylaxis	 is	usually	given	over	 the	
period	of	main	immunosuppression	(		̴100	days)	with	the	goal	to	suppress	viremia	in	the	
initial	 month	 following	 transplantation.	 In	 pre‐emptive	 therapy,	 patients	 receive	
antiviral	 treatment	when	 they	are	at	particular	 risk	 for	 clinically	 important	disease	as	
shown	by	 a	 particular	 laboratory	or	 clinical/epidemiologic	 finding	 indicating	 a	 risk	 of	
CMV	infection.	This	requires	serial	monitoring	of	population	at	higher	risk	with	sensitive	
and	rapid	detection	methods	(via	DNAemia	by	PCR	in	blood	or	pp65	antigenaemia).		
Similar	 reduction	 of	 CMV‐associated	 morbidity	 and	 mortality	 were	 shown	 with	 both	
strategies,	 which	 are	 currently	 recommended	 by	 guidelines	 [77,	 78].	 However,	 some	
concerns	 remains	 regarding	 the	 prevention	 of	 CMV	 disease.	 Although	 pre‐emptive	
therapy	reduces	the	exposure	of	patients	to	the	risks	of	side	effects	associated	with	long‐
term	drug	treatment,	 it	may	not	prevent	 low‐level	asymptomatic	viral	replication	with	
the	risk	of	indirect	effects	of	CMV	infection	[79‐81].	In	a	recent	prospective	cohort	study	
of	 including	 over	 95%	 of	 SOT	 recipients	 in	 Switzerland	 (1239	 SOT	 patients	 between	
2008	and	2011),	a	6%	incidence	of	CMV	disease	was	reported	after	a	median	follow‐up	
of	1	year.	Although	the	incidence	was	similar	regarding	the	antiviral	preventive	strategy,	
prophylaxis	was	shown	to	delay	the	CMV	event	after	the	period	of	treatment,	whereas	
pre‐emptive	 therapy	 was	 associated	 with	 an	 inferior	 transplant	 outcomes	 suggesting	
asymptomatic	viremia	early	after	transplantation	[82].	
Despite	 the	 use	 of	 prophylaxis	 or	 pre‐emptive	 therapy,	 “late‐onset	 CMV	 disease”	
resulting	 from	 virus	 reactivation	 within	 the	 1st	 year	 following	 the	 antiviral	 therapy	
period	still	occurs	in	approximately	20	to	30%	of	patients	at	risk	[83].	The	typical	course	
of	 treatment	 in	 this	 case	 is	 3‐4	 weeks	 of	 acute	 therapy	 until	 all	 evidence	 of	 virus	
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replication	 is	 eliminated,	 clinical	 and	 laboratory	 improvement,	 and	 followed	 by	 2‐4	
months	of	secondary	prophylaxis	[64].	
4.2 Antiviral	drugs	
Three	 antiviral	 agents	 are	 currently	 approved	 for	 the	 systemic	 treatment	 of	 CMV	
infection	 and	 all	 belong	 to	 the	 nucleoside	 class	 of	 compounds:	 ganciclovir	 (GCV),	
cidofovir	(CDV)	and	foscarnet	(FOS).	Formivirsen,	an	anti‐sense	RNA,	is	approved	for	the	
local	 treatment	of	CMV	retinitis.	To	date	no	anti‐CMV	agent	has	been	approved	for	the	
management	of	congenital	CMV	disease.			
4.2.1 Ganciclovir	
First	specific	antiviral	agent	approved	for	the	treatment	of	CMV	disease	(1989	for	CMV	
retinitis),	GCV	is	the	first‐line	choice	for	the	treatment	of	CMV	infection	in	the	majority	of	
clinical	indications	[84,	85].	Acyclic	nucleoside	analogue	of	2’‐deoxyguanosine,	GCV	is	a	
prodrug	that	is	required	to	be	tryphosphorylated	to	be	active,	first	by	the	CMV‐encoded	
pUL97	protein	kinase,	then	by	the	cellular	enzymes	(Figure	5).	GCV	triphosphate	acts	as	
competitive	 inhibitor	of	 the	viral	DNA	polymerase	(pUL54)	resulting	 in	a	slower	chain	
elongation	once	incorporated	in	place	of	dGTP	[86,	87].	In	1994,	an	oral	formulation	was	
introduced	 in	 addition	 to	 the	 original	 intravenous	 (IV)	 formulation	 (Cytovene‐IV®,	
Roche),	 for	 prophylaxis	 and	 maintenance	 therapy.	 However,	 the	 low	 bioavailability	
(approximately	6%)	and	the	high	pill	burden	of	this	formulation	were	increasing	the	risk	
of	 lower	 systemic	 exposure	 and	 the	 emergence	 of	 drug	 resistance.	 In	 2000,	
valganciclovir	(an	l‐valyl	ester	of	GCV)	was	approved	with	an	oral	bioavailability	around	
60%	achieving	a	 similar	 systemic	drug	exposure	 than	 the	 IV	 formulation	with	a	once‐
daily	administration.	The	major	side	effect	associated	with	GCV	therapy	is	neutropenia,	
which	can	be	dose	limiting	and	may	be	a	risk	for	opportunistic	infections.	A	risk	of	renal	
toxicity	 may	 also	 occur	 in	 combination	 administration	 with	 other	 nephrotoxic	
compounds	(cyclosporine	A)	[88].		
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Figure	5:	Mechanisms	of	action	of	systemic	antiviral	agents	approved	for	
treatment	of	CMV	infection.	
Reproduced	from	Gilbert	and	Boivin,	AAC,	2005[89]	
4.2.2 Cidofovir	
Cidofovir	(Vistide®,	Gilead)	is	a	phosphonomethoxy	analogue	of	cytosine	with	a	broad‐
spectrum	antiviral	activity	against	herpesviruses	but	also	other	DNA	viruses	(small	pox	
virus)	[90].	Although	sharing	the	mechanism	of	action	of	GCV	as	a	competitive	inhibitor	
of	the	viral	DNA	polymerase,	CDV	carries	a	phosphate	group	and	is	thus	converted	in	his	
active	 form	 by	 the	 cellular	 enzymes	 only	 (Figure	 5).	 Marketed	 in	 1996,	 CDV	 is	 only	
available	in	IV	formulation	and	used	as	a	second‐line	treatment	only,	mainly	because	of	
the	great	risk	of	severe	nephrotoxicity	[91].	CDV	is	also	associated	with	neutropenia.	
4.2.3 Foscarnet	
Second	 drug	 approved	 for	 treatment	 of	 CMV	 retinitis	 in	 1991,	 Foscarnet	 (Foscavir®,	
AstraZeneca)	is	a	trisodium	salt	of	phosphormophonic	acid.	Contrary	to	GCV	or	CDV,	FOS	
does	not	require	chemical	modification	for	antiviral	activation	(Figure	5).	It	binds	to	the	
pyrophosphate‐binding	site	of	the	viral	DNA	polymerase	and	blocks	the	cleavage	of	the	
pyrophosphate	group	from	the	terminal	nucleoside	triphosphate	added	to	the	growing	
DNA	 chain	 [92].	 Only	 available	 in	 IV	 formulation	 as	 well,	 FOS	 is	 used	 as	 second‐line	
therapy	for	patients	who	failed	GCV	therapy	due	to	viral	resistance	or	 to	dose‐limiting	
neutropenia	 or	 leukopenia	 [85].	 However,	 due	 to	 the	 risk	 of	 renal	 impairment,	 FOS	
administration	 requires	 slow	 infusion,	 extensive	 prehydratation	 and	 frequent	
monitoring	of	serum	creatinine	levels.	[93]	 	
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4.2.4 Formivirsen	
Formivirsen	 (Vitravene®,	 Isis	 Pharmaceuticals)	 is	 a	 21‐nucleotide	 anti‐sense	 RNA	
targeting	specifically	 the	major	 IE	 transcriptional	unit.	Approved	 in	1998	as	a	 second‐
line	 treatment	 of	 CMV	 retinitis	 in	 AIDS	 patients,	 Formivirsen	 is	 administrated	 by	
intraocular	injection	[94].		
4.2.5 Compounds	in	development	
Two	antiviral	compounds	are	currently	in	clinical	development	for	the	management	and	
the	prevention	of	HCMV	infection.			
Maribavir	is	an	UL97	kinase	inhibitor,	shown	in	vitro	to	inhibit	viral	DNA	assembly	and	
inhibits	egress	of	viral	 capsids	 from	the	nucleus	of	 infected	cells.	Despites	a	good	oral	
bioavailability,	 low	 host	 cell	 toxicity,	 maribavir	 failed	 as	 prophylaxis	 to	 prevent	 CMV	
disease	in	transplant	patients	[95,	96].	However,	following	recent	positive	outcomes	of	
the	 management	 with	 maribavir	 of	 12	 patients	 with	 resistant	 CMV	 infection	 [97],	
additional	phase	2	studies	are	ongoing	in	hematopoietic	stem	cell	or	SOT	recipients.	
Letermovir	(AIC246)	belongs	to	a	novel	class	of	low‐molecular‐weight	compounds	with	
strong	 in	 vitro	 anti‐CMV	 activity	 in	 laboratory	 strains,	 clinical	 isolates	 or	 different	
resistant	strain	to	approved	drugs.	Letermovir	 interferes	with	the	UL56	subunit	of	 the	
viral	terminase	complex	blocking	the	viral	DNA	cleavage/packaging	in	the	late	phase	of	
the	replication	cycle	[98].	Favorable	outcomes	were	reported	in	a	phase	2a	clinical	study	
for	 the	 use	 of	 letermovir	 as	 preemptive	 therapy	 and	 in	 a	 phase	 2b	 study	 for	 HCMV	
prophylaxis	in	stem	cell	transplant	recipients	[99].		
4.2.6 Resistance	to	antiviral	drugs	
Drug‐resistant	 CMV	 infection	 was	 first	 seen	 in	 patients	 with	 AIDS.	 Prior	 to	 the	
introduction	of	HAART,	several	studies	reported	clinical	isolates	from	AIDS	patients	with	
GCV‐	resistance	with	an	incidence	of	2‐7%	after	2‐3	months	of	therapy	and	15‐28%	after	
9	 or	 18	 months	 [88,	 89].	 HCMV	 resistance	 is	 today	 an	 emerging	 problem	 in	 SOT	
recipients.	 The	 incidence	 and	 temporal	 emergence	 of	 GCV	 resistance	 varies	 greatly	
according	 to	 the	 type	 of	 transplant,	 the	 different	 strategies	 of	 treatment	 and	 the	
immunosuppressive	regimen	used.	In	a	retrospective	study	of	240	SOT	recipients,	GCV‐
resistance	 rates	 occurs	 in	 2.1%	of	 all	 patients	 and	 in	 7%	of	D+/R‐	 subjects	 (67	 out	 of	
240),	with	the	highest	frequency	in	kidney‐pancreas	or	pancreas	recipients	(21%)	and	
kidney	recipients	(5%)	[89].	
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HCMV	resistance	to	GCV	is	associated	with	mutations	mapped	to	both	UL54	(viral	DNA	
polymerase)	and	UL97	(protein	kinase)	genes	[100],	UL97	mutations	been	identified	by	
genotypic	studies	in	over	90%	of	GCV‐resistant	HCMV	clinical	isolates	[101].	These	point	
mutations	or	small	deletions	were	located	in	the	codons	460,	520	or	in	the	cluster	590‐
607	 of	 the	 UL97	 genes,	 resulting	 in	 impaired	 drug	 phosphorylation	 but	 without	
preventing	 the	 protein	 kinase	 function	 [89].	 Being	 the	 only	 drug	 requiring	 a	
monophosphorylation,	theses	mutations	do	not	affect	the	antiviral	potential	of	the	other	
nucleoside	 analogues.	 In	 contrast,	 mutations	 in	 the	 pol	 gene	 UL54	 generally	 occur	 in	
specific	 conserved	 subdomains	 and	 may	 confer	 cross‐resistance	 to	 CDV	 or	 less	
commonly	FOS	[102].	However,	several	clinical	isolates	were	shown	to	have	mutations	
in	both	the	UL54	and	the	UL97	genes	and	to	be	cross‐resistant	to	GCV,	CDV	and/or	FOS	
[103].	
Altogether,	risk	factors	for	the	emergence	of	GCV	resistance	include	suboptimal	plasma	
or	 tissue	 drug	 concentration,	 a	 sustained	 and	 profound	 immunosuppression	 status,	 a	
high	HCMV	load,	frequent	episodes	of	HCMV	disease	and	frequent	discontinuation	of	the	
treatment	due	to	toxicity.	In	addition,	the	lack	of	HCMV‐specific	immunity	(D+/R‐	group)	
is	a	major	risk	factor	in	SOT.		
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II. Statins:	not	just	a	family	of	cholesterol	
lowering	drug	
Cardiovascular	 diseases	 (CVD)	 are	 the	 principal	 cause	 of	 mortality	 in	 developed	
countries.	An	estimated	17.1	million	people	died	from	CVD	in	2004,	representing	29%	of	
all	 global	 deaths	 (WHO,	 Fact	 sheet	 317,	 January	 2011).	 Elevated	 level	 of	 serum	
cholesterol	or	hypercholesterolemia	 (HC)	 is	one	major	 risk	 factors	modifiable	 for	CVD	
prevention.	 A	 strong	 association	 has	 been	 established	 between	 HC	 and	 increased	
atherosclerotic	 disease,	 the	 underlying	 disorder	 in	 the	 majority	 of	 patients	 [104].	
Statins,	a	family	of	potent	inhibitors	of	the	cholesterol	biosynthesis	pathway,	is	the	most	
commonly	prescribed	treatment	for	HC.	Interestingly,	statin	therapy	appears	to	promote	
additional	effects	that	are	independent	from	changes	in	serum	cholesterol	level.	Among	
them,	antiviral	activity	against	several	viruses	has	been	reported.	
1. Cardiovascular	disease	and	cholesterol	lowering	
drugs	
1.1 Cardiovascular	risk	factors	
Running	from	1948	to	1971,	the	Framingham	Heart	Study	was	the	first	large‐scale	study	
to	evaluate	the	causes	of	atherosclerotic	heart	disease.	Several	main	risks	factors	were	
defined	 which	 cannot	 be	 influenced	 (age,	 gender,	 heredity)	 but	 some	 are	 adjustable,	
such	 as	 high	blood	pressure,	HC,	 smoking,	 obesity	 or	 diabetes	 [104‐108].	 The	 level	 of	
total	cholesterol	in	the	blood	and	in	particular	the	ratio	between	high‐density	and	low‐
density	 lipoprotein	 (LDL)	 is	 now	 considered	 a	 strong	 predictor	 of	 the	 likelihood	 to	
develop	 coronary	 heart	 disease.	 Cholesterol	 is	 an	 essential	 component	 of	 cell	
membranes,	the	source	being	by	one‐third	food	and	by	two‐thirds	synthesis	in	the	liver.	
Thus,	diet	alone	may	not	result	in	a	great	enough	reduction	in	cholesterol	levels	and	may	
need	to	be	combined	with	cholesterol‐lowering	drugs.	
1.2 Statins	introduction	and	clinical	benefits		
The	first	identification	of	a	fungal	metabolite	(compactin)	blocking	cholesterol	synthesis	
was	done	 in	1971	by	Endo	 et	al	 [109].	Although	 its	 administration	 to	 rats	 resulted	 in	
significant	 inhibition	 of	 cholesterol	 biosynthesis,	 the	 unacceptable	 hepatocellular	
toxicity	made	 any	 further	 clinical	 development	 impossible.	 In	 1978,	 a	 new	metabolite	
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called	 lovastatin	 was	 isolated	 from	 Aspergillus	 terreus	 and	 displayed	 a	 more	 potent	
inhibition	 of	 the	 3‐hydroxy‐3‐methylglutaryl	 coenzyme	 A	 (HMG‐CoA)	 reductase,	 the	
enzyme	catalyzing	the	rate‐limiting	step	of	the	cholesterol	biosynthesis	pathway	(Figure	
7).	Without	 hepatocellular	 toxicity	when	 administrated	 in	 rats,	 lovastatin	 became	 the	
first	of	its	class	of	cholesterol‐lowering	agents	to	be	approved	for	clinical	use	in	human	
[110].	 Since	 then,	 three	 generations	 of	 statins,	 both	 natural	 and	 chemically	 modified,	
have	 been	 commercially	 introduced:	 pravastatin	 and	 fluvastatin	 (first	 generation),	
atorvastatin	 and	 simvastatin	 (second	 generation),	 and	 finally	 rosuvastatin	 and	
pitavastatin	(third	generation)	[111].	Although	all	statins	share	an	HMG‐like	moiety	and	
competitively	 inhibit	 the	 HMG‐CoA	 reductase	 by	 similar	 mechanism,	 structural	
adaptations	were	used	to	improve	pharmacokinetics,	drug‐drug	interactions	and	safety	
[112].		
Since	 introduction	 into	 the	marketplace	 in	1986,	 statins	have	become	one	of	 the	main	
medications	 thanks	 to	 their	 efficient	 prevention	 of	 both	 primary	 and	 secondary	 CVD	
[113‐118].	 Interestingly,	 two	 mechanisms	 were	 shown	 to	 be	 involved	 into	 statin‐
mediated	reduction	of	serum	cholesterol	levels:	the	reduction	of	endogenous	cholesterol	
synthesis	 via	 the	 HMG‐CoA	 reductase	 inhibition	 and	 the	 increase	 of	 cholesterol	
clearance	from	the	bloodstream	via	the	increases	in	hepatic	LDL‐containing	cholesterol	
receptor	activity	[119].	Clinical	data	reporting	a	decrease	 in	cardiovascular	events	and	
regression	 of	 atherosclerosis,	 especially	 following	 early	 initiation	 of	 statins,	 strongly	
suggested	 statins	 also	 exert	 some	 beneficial	 effects	 beyond	 their	 ability	 to	 lower	
cholesterol.	 In	 2006,	 the	 ARMYDA	 study	 reported	 a	 strong	 reduction	 of	 myocardial	
infarction	 during	 or	 shortly	 after	 coronary	 intervention	 as	 well	 as	 a	 concomitant	
attenuation	of	post‐procedural	endothelial	inflammatory	response	[120,	121].		
This	 anti‐inflammatory	 activity	 of	 statins	 is	 supported	 by	 other	 studies	 (PRINCE,	
PROVE‐IT/TIMI22,	REVERSAL,	MIRACL)	where	statin	therapy	resulted	in	a	reduced	risk	
of	 acute	 coronary	 syndromes	 in	 patients	with	 normal	 LDL	 cholesterol	 (<3.4	mmol/L)	
but	increased	C‐reactive	protein	(CRP)	concentration,	a	marker	of	vascular	inflammation	
[122,	 123].	 The	 JUPITER	 study,	 a	 4‐year	 trial	 designed	 to	 assess	 the	 benefit	 of	 statin	
therapy	in	patients	with	increased	inflammatory	response	(defined	by	a	high‐sensitivity	
CRP	 level)	but	with	normal	LDL‐cholesterol	 level,	 provided	 the	 strongest	 evidences	of	
the	 beneficial	 use	 of	 statins	 in	 primary	 prevention	 of	 cardiovascular	 risks	 [124].	 The	
study	was	discontinued	after	1.9	years	only,	having	reached	a	significant	47%	reduction	
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of	various	cardiovascular	events	in	the	group	of	interest,	over	17	802	men	and	women	
recruited	and	randomized	for	rosuvastatin	or	placebo	treatment.		
1.3 Atherosclerosis,	an	ongoing	inflammatory	disease	
The	 understanding	 of	 statin	 therapy	 benefits	 in	 prevention	 of	 CVD	 is	 related	 to	 the	
pathogenesis	 of	 atherosclerosis.	 Atherosclerosis	 is	 a	 complex,	 slow	 process,	 chronic	
inflammatory	 response	 of	 arterial	 blood	 vessels,	 resulting	 in	 accumulation	 of	
cholesterol‐dense	macrophages,	smooth	muscles	cells	proliferation	and	the	elaboration	
of	multiple	plaques,	leading	to	arteries	thickening	with	the	risk	of	thrombosis	[125].		
	
Figure	6:	Key	steps	in	the	development	of	atherosclerosis	
Reproduced	from	R.	Vogel,	Am	J	Med,	1999[126]	
The	 disease	 is	 thought	 to	 be	 initiated	 by	 a	 complex	 interplay	 between	 endothelial	
dysfunction	 and	 lipids	 accumulation	 and	 modification	 (Figure	 6).	 Cardiovascular	 risk	
factors	tend	to	perturbate	the	endothelium	main	role	of	regulation	of	the	vessel	tone	in	
response	 to	 physical	 and	 humoral	 conditions,	 via	 the	 secretion	 of	 several	 biologically	
active	 species	 with	 autocrine,	 paracrine	 and	 endocrine	 metabolism.	 In	 particular,	
oxidized	 LDL	 cholesterol	 stimulates	 vascular	 cells	 to	 produce	 inflammatory	 cytokines	
and	recruit	leukocytes	[126‐128].	After	adhering	to	the	activated	endothelial	monolayer,	
monocytes	migrate	 into	the	 intima	and	mature	 into	macrophages,	contributing	to	 lipid	
uptake	and	finally	turning	into	foam	cells.	The	lesion	progression	involves	the	migration	
of	vascular	smooth	muscle	cells	(VSMC)	from	the	media	to	the	intima	and	the	synthesis	
of	extracellular	matrix	macromolecules.	Extracellular	 lipid	derived	 from	dead	or	dying	
cells	 (macrophages	and	VSMC)	can	accumulate	 in	 the	central	 region	of	a	plaque,	often	
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denoted	the	 lipid	or	necrotic	core,	 together	with	cholesterol	crystals	and	microvessels.	
The	 ultimate	 complication	 of	 atherosclerosis	 occurs	 in	 case	 of	 rupture	 of	 the	 plaque,	
causing	 thrombosis	 and	 leading	 to	 acute	 ischemic	 episodes	 in	 both	 cardiac	 and	
peripheral	vascular	systems	[129].		
1.4 Clinical	manifestations	and	molecular	biology	of	statins	
pleiotropic	effects	
Statins	 have	 been	 introduced	 as	 inhibitors	 of	 the	 HMG‐coA	 reductase	 to	 lower	 LDL‐
cholesterol	 synthesis	 and	 serum	 levels.	 However,	 this	 enzyme	 is	 catalyzing	 the	 rate‐
limiting	step	of	 the	mevalonate	biosynthetic	pathway,	a	complex	biochemical	pathway	
generating	 several	 fundamental	 end‐products,	 including	 cholesterol,	 isoprenoids,	
dolichol	 (protein	 glycosylation),	 ubiquinone	 (respiratory	 chain	 activity),	 and	
isopentenyladenine	(Figure	7)	[130].	
Thus,	 by	 inhibiting	 the	 synthesis	 of	 mevalonate,	 statins	 also	 prevent	 the	 synthesis	 of	
essential	 isoprenoids	 intermediates	 of	 such	 as	 the	 farnesyl	 and	 geranylgeranyl	
pyrophosphate	(FPP	and	GGPP,	respectively)	that	are	required	for	the	post‐translational	
modification	(isoprenylation)	of	various	small	GTP‐binding	proteins	including	Ras,	Rap,	
Rab,	 Rho,	 nuclear	 lamins,	 and	 the	 heterotrimeric	 G‐protein	 c‐subunit	 [119,	 131,	 132].	
Isoprenylation	 is	 needed	 for	 anchoring	 these	 signaling	 proteins	 to	 the	 cellular	
membranes	 in	 close	 proximity	 to	 growth	 factor	 receptors,	 to	 be	 activated	 following	
receptor	activation,	and	subsequently	participate	 in	 turning	on	downstream	mitogenic	
signaling	pathways	such	as	MAPK	and	Akt	[133].	Ras	farnesylation	was	shown	to	induce	
VSMC	migration	and	proliferation,	Rho	GTPases	to	be	 involved	in	the	regulation	of	the	
actin	cytoskeleton,	the	cellular	migration,	the	cell	division	and	adhesion,	playing	a	major	
role	 in	 vascular	 structure	 and	 function	 [134,	 135].	 Thus,	 by	 targeting	 the	 HMG‐CoA	
reductase,	 statins	 not	 only	 block	 cholesterol	 biosynthesis,	 but	 also	 affect	 key	 proteins	
involved	 in	 vascular	 inflammation	 and	 remodeling	 [136‐138].	 These	 cholesterol‐
independent	effects	or	so‐called	“pleiotropic”	effects	are	not	limited	to	endothelial	cells.	
Indeed,	statins	being	mostly	lipophilic	are	considered	to	enter	cells	by	passive	diffusion	
through	 the	 cell	 membrane	 and	 to	 affect	 multiple	 cell	 populations	 relevant	 to	 both	
inflammatory	 and	 immune	 responses,	 including	 B	 cells,	 T	 cells,	 regulatory	 T	 cells,	
macrophages,	dendritic	cells	or	platelets	[139].	
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Figure	7:	The	mevalonate	pathway	
Reproduced	from	A.	Corsini	et	al.,	Pharmacology	&	Therapeutics,	1999	[130]	
The	reduction	of	vascular	inflammation	is	 likely	to	be	an	essential	modus	operandi	for	
statins	to	exert	vasculoprotective	effects	[138,	140,	141].	Statins	were	shown	to	reduce	
the	amount	of	inflammatory	cells	in	atherosclerotic	plaques	[142].	Indeed,	the	inhibition	
of	 the	expression	of	 the	adhesion	molecules	and	 the	major	histocompatibility	complex	
class	 II	 by	 statin	 was	 demonstrated	 in	 EC	 and	 monocytes	 [143‐145].	 One	 important	
characteristic	 of	 endothelial	 dysfunction	 is	 the	 decreased	 synthesis	 and	 activity	 of	
endothelial‐derived	nitric	oxide	(eNOs),	a	major	inhibitor	of	the	atherogenic	process	in	
thus	that	it	mediates	vasodilatation,	inhibits	platelet	aggregation	and	VSMC	proliferation	
and	 prevents	 monocyte	 adhesion	 [146].	 eNOs,	 which	 expression	 is	 reduced	 in	
proatherogenic	 conditions	 (hypoxia,	 oxydised‐LDL‐C	 or	 cytokines),	 is	 upregulated	 by	
statins	who	increased	eNOs	mRNA	stability	through	the	inhibition	of	RhoA	[147].	A	third	
mechanism	 recently	 revealed	 might	 also	 be	 involved	 in	 these	 immune‐modulatory	
effects.	Lovastatin	and	other	statins	were	shown	to	specifically	bind	to	an	allosteric	site	
of	 the	 leukocyte	 function‐associated	antigen‐1	 (LFA‐1)	 resulting	 in	 inhibition	of	LFA‐1	
binding	 to	 intracellular	 adhesion	 molecule	 (ICAM‐1).	 Interestingly,	 this	 selective	
inhibition	is	unrelated	to	the	inhibition	of	HMG‐CoA	reductase	[148,	149].	
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Altogether,	 the	 therapeutic	effects	of	statins	are	a	combination	of	cholesterol‐lowering	
and	 cholesterol‐independent	 effects	 at	 both	molecular	 and	 cellular	 levels	 resulting	 in	
wide‐ranging	clinical	benefits	in	CVD	prevention,	including	improvement	or	restoration	
of	 the	 endothelial	 function,	 enhancement	 of	 the	 atherosclerotic	 plaques	 stability	 and	
decrease	of	vascular	inflammation.		
1.5 Antiviral	activity	of	statins	
Interestingly,	 statins	were	 also	 reported	 to	 exert	 beneficial	 properties	 against	 a	wide‐
range	of	pathogens.	The	mechanisms	of	the	in	vitro	antiviral	activities	of	statins	against	
several	viruses	are	resumed	in	Table	2.		
Obviously,	cholesterol	reduction	is	the	first	mode	of	action	through	which	statins	might	
impair	viral	infections.	Cholesterol	is	an	essential	component	of	cellular	membranes	and	
cholesterol	 depletion	 could	 thus	 interfere	 with	 several	 steps	 of	 the	 virus	 replication	
cycle.	Statin‐mediated	reduction	of	cellular	cholesterol	 in	vitro	was	shown	to	affect	the	
replication	 of	 pseudorabies	 virus,	 poliovirus	 or	 rotavirus	 [150,	 151].	 The	 major	 role	
played	 by	 prenylated	 proteins	 into	 intracellular	 signaling	 pathways	 explained	 the	
antiviral	activity	of	statins	against	 the	respiratory	syncytial	virus,	 the	hepatitis	C	virus	
(HCV)	replication	and	HIV‐1.	Interestingly,	different	mechanisms	were	reported	in	HIV‐1	
inhibition,	including	the	inhibition	of	LFA‐1	binding	to	ICAM‐1.	
In	vivo	evaluation	of	 anti‐HIV	potential	of	 statins	 revealed	a	decrease	of	 the	viral	 load	
and	 increase	 of	 the	 CD4+	 cell	 counts	 after	 1	week	 of	 treatment	 in	 an	 acute	model	 of	
infection	 in	 SCID	mice	 grafted	 with	 adult	 human	 peripheral	 blood	mononuclear	 cells	
[152].	However,	the	clinical	confirmations	of	these	data	are	controversial.	In	a	proof‐of‐
concept	small‐scale	study,	del	Real	et	al.	reported	a	net	reduction	of	viral	RNA	loads	and	
in	 general,	 an	 increase	 of	 the	 CD4+	 T	 cell	 counts	 in	 six	 chronically	HIV‐1	 patients	 not	
receiving	HAART.	The	discontinuation	of	statin	treatment	was	followed	by	a	rebound	in	
viral	load.	In	contrast,	2	studies	evaluating	atorva‐	or	simvastatin	in	HIV‐1	patients	after	
HAART	discontinuation	did	not	report	any	significant	reduction	in	the	viral	 loads	or	in	
the	CD4+	cell	 loss	over	12	weeks	of	 treatment,	despite	 their	ability	 to	 reduce	patients’	
serum	 cholesterol	 levels	 [153,	 154].	 Finally,	 when	 patients	 with	 stable	 antiretroviral	
therapy	were	 assessed,	 pravastatin	 did	 not	 exert	 a	 clear	 effect	 on	 viral	 load	 but	 was	
associated	 with	 substantial	 viral	 rebound	 in	 some	 patients	 after	 discontinuation	 of	
treatment	[155].	Altogether,	these	studies	do	not	support	the	uses	of	statins	as	antiviral	
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agents	 in	 HIV‐infected	 patients	 outside	 of	 their	 use	 as	 cholesterol‐lowering	 drugs.	
Moreover,	significant	drug‐drug	interactions	have	been	reported	between	some	statins	
and	protease	inhibitors	exacerbating	their	inherent	toxicities	[156].	
The	 anti‐HCV	 activity	 of	 statins	 is	 probably	 the	 most	 studied	 one,	 alone	 or	 in	
combination	with	selective	HCV	inhibitors.	 In	vitro,	 the	potency	of	the	different	statins	
was	 evaluated.	 Atorvastatin,	 fluvastatin,	mevastatin	 and	 simvastatin	were	 reported	 to	
have	 similar	 anti‐HCV	 activity.	 Lovastatin	was	 shown	 to	 be	 less	 effective	 in	 inhibiting	
HCV	replication	and	pravastatin	not	to	exert	any	[157,	158].	The	additive	activity	of	most	
statins	 against	 HCV	 was	 demonstrated	 in	 vitro	 with	 IFN‐α	 as	 well	 as	 with	 different	
specific	 HCV	 polymerase	 inhibitors	 and	 protease	 inhibitors.	 Moreover,	 drug‐resistant	
HCV	 replicon	 exhibited	 similar	 susceptibility	 to	mevastatin,	 and	 the	 combination	with	
the	non‐nucleoside	polymerase	inhibitor	HCV‐796	delayed	or	prevented	the	emergence	
of	 resistant	 replicon.	 Clinical	 evaluation	of	 statins	 on	HCV	 is	 limited.	Atorvastatin	was	
investigated	 in	 a	 12‐weeks	 prospective	 trial	 in	 HCV‐infected	 patients	 who	 required	
treatment	for	hypercholesterolemia.	Despite	the	reduction	of	the	serum	cholesterol,	no	
significant	 change	 in	 HCV	 RNA	 levels	 was	 reported	 [159].	 In	 contrast,	 fluvastatin	
evaluated	as	monotherapy	 showed	modest,	 variable	 and	often	 short‐lived	 suppressive	
effects	 on	 HCV	 viral	 loads	 in	 chronic	 HCV	 carriers	 [160].	 Recently,	 rosuvastatin	 was	
reported	 to	 be	 beneficial	 in	 addition	 to	 IFN‐α	 and	 ribavirin	 treatment	 in	 chronic	HCV	
patients	 with	 nonalcoholic	 fatty	 liver	 disease	 and	 to	 significantly	 reduce	 viremia,	
steatosis,	and	fibrosis	without	causing	side	effects	[161].	
In	 2003,	 Horne	 et	 al.	 evaluated	 the	 effect	 of	 statin	 therapy,	 as	 part	 of	 the	 normal	
medication,	among	CMV	seropositive	patients	with	angiographically	significant	coronary	
artery	disease	[162].	Statins	reduced	the	increased	mortality	rates	associated	with	CMV‐
seropositivity.	 The	 authors	 attributed	 these	 beneficial	 effects	 of	 statins	 to	 immune‐
altering,	 anti‐inflammatory	or	 antioxidant	properties,	 rather	 than	 to	 a	direct	 anti‐viral	
effect.	 However,	 fluvastatin	 has	 been	 shown	 to	 restrain	 HCMV	 replication	 in	 human	
umbilical	 vein	 EC	 by	 inhibiting	 IE	 antigen	 expression	 and	 subsequent	 DNA	 synthesis	
[163].	 A	 reduction	 of	NF‐κB	 binding	 activity	 by	 fluvastatin	was	 suspected	 to	 limit	 the	
transactivation	of	the	CMV‐IE	promotor.		
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Table	2:	Antiviral	activities	of	statins	
[150‐152,	157,	158,	160,	164‐172]	
	
Virus Statins In vitro / 
In vivo
cholesterol 
depletion/
pleiotropic
Results / Mechanism Viral target Cellular target Publication
Pol iovi rus
 picornaviridae
s imvastatin in vitro
cholesterol   
depletion
Impairement of the  vira l  genome  transcription vi ra l  RNA transcription Intracel lular ves icles  formation S. Liu et al.
BBRC, 2006
Rotavi rus
reoviridae
lovastatin in vitro
cholesterol   
depletion
Defective  vi ra l  particle  assembly ND ‐ K.V. Mohan et al.
Arch Virol, 2008
Pseudorabies  vi rus
alphaherpesviridae
lovastatin in vitro
cholesterol   
depletion
Reduced infectivi ty and stabi l i ty of progeny vi rus ‐ ‐ A.S. Desplanques  et al.
Virus Research, 2010
in vivo (mice)
Diminishes  RSV repl i cation and 
RSV‐induced i l lness  in mice ‐ ‐
in vitro  Inhibi t RSV‐mediated cel l ‐to‐cel l  fus ion fus ion glycoprotein F RhoA membrane  loca l i sation
Dengue  virus
flaviviridae
lovastatin in vitro both
 Impai red vira l  assembly process  in the   
endoplasmic reticulum ‐ Rab5 and Rab8 proteins  ?
M. Martí nez‐Gutierrez et al.
Intervirology, 2011
Hepati ti s  B vi rus
flaviviridae
s imvastatin in vitro ND
Effective  inhibtion of HBV repl ication
Potentiate  al l  four l i censed nucleos i te  
 analogues  anti ‐HBV activi ty
ND ND
T. Bader et al .
Antiviral Research, 2010
lovastatin in vitro pleiotropic
Prevent the  assembly of HCV repl ication 
  complex
HCV NS5A 
non structura l  protein
FLB2 
geranygeranylation
J. Ye  et al ., PNAS, 2003
C. Wang et al . Mol Cell ,2005
atorvastatin
fluvastatin
lovastatin
pitavastatin
s imvastatin
in vitro pleiotropic
Prevent HCV RNA repl ication with various
   potentia l : pita>flu>ato>s im>lov 
Enhance  the  anti ‐HCV activi ty of IFN‐α
‐ ‐
M. Ikeda  et al .
Hepatology, 2006
J Pharmacol Sci, 2007
mevastatin
s imvastatin
in vitro pleiotropic
Additive  antivi ra l  effect with HCV polymerase   
and protease  inhibi tors
Prevent the  selection of drug‐res is tant HCV 
repl icon
‐ ‐ L. Delang et al .
Hepatology, 2009
in vivo (mice)
Decrease  vi ra l  load and increase  CD4+ cel l  
counts  in acute  infection model ‐ ‐
in vitro Inhibi tion of virus  entry and budding ND Rho GTPases
(gp120‐CXCR4 colocal i sation?)
lovastatin in vitro pleiotropic Diminish HIV‐1 attachment to target cel l s ‐ block ICAM‐1‐LFA‐1 interactions J.F. Giguère  et al .
J Virol, 2004
lovastatin
mevastatin 
s imvastatin
in vitro pleiotropic
Preferentia l  reduction of CD4+ lymphocytes  
infection with R5 virus  as  compared to X4  ‐
 decreased CCR5 cel l  surface  express ion 
increased secretion of RANTES
A.A: Nabatov et al .
Plos One, 2007
lovastatin
s imvastatin
in vitro pleiotropic
Suppress   HIV‐1 virion release  from TNF‐α 
s timulated la tently infected cel ls ‐
Rab11a  GTPase  
(faci l i ta ting intracel lular ves icles  
traficking)
T. Amet et a l .
J Mic Inf, 2008
HIV‐1
retroviridae
lovastatin pleiotropic
G. del  Real  et al .
J Exp Med, 2004
Respi ratory Syncytia l  
Virus
paramyxoviridae
lovastatin pleiotropic
T.L. Gower et al.
AAC, 2001
Hepati ti s  C vi rus
flaviviridae
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 Aims	of	the	study	
In	the	absence	of	vaccines	against	HCMV	and	considering	the	drawbacks	limiting	the	use	
of	 current	antiviral	drugs,	 there	 is	an	urgent	need	 for	new	 therapeutic	approaches	 for	
the	management	of	acute	HCMV	disease	in	immunocompromised	patients.	Beyond	anti‐
infective	therapies,	other	medications	may	provide	a	means	to	treat	infection‐associated	
effects,	especially	the	role	played	by	HCMV	into	the	pathogenesis	of	atherosclerosis	and	
ultimately	 prevention	 of	 cardiovascular	 diseases.	 One	 effective	 strategy	 consists	 in	
looking	for	known	drugs	with	a	good	safety	profile	that	also	affect	viruses.		
Statins	are	a	well‐tolerated	and	extensively	studied	group	of	cholesterol‐lowering	drugs,	
exhibiting	 strong	 anti‐inflammatory	 and	 immune‐modulatory	 activities	 as	 well	 as	
antiviral	 effects	 on	 different	 viruses	 alone	 or	 in	 combination	 with	 selective	 antiviral	
inhibitors.	So	far,	despite	the	 large	number	of	statins	currently	used	in	clinic	and	their	
differences	 in	 term	of	 tissue	permeability	and	metabolism,	only	 fluvastatin	was	 tested	
for	anti‐CMV	activity.	
	
This	study	was	aiming	to:	
#	1.		 Explore	 the	 in	 vitro	 anti‐cytomegalovirus	 activity	 of	 various	 statins	 in	 two	
relevant	 cell‐types	 in	 HCMV	 infection,	 human	 endothelial	 cells	 from	 various	 vascular	
beds	and	fibroblasts	
#	2.		 Provide	 insights	 into	 the	 cellular	 and	 molecular	 mechanisms	 of	 statins’	 anti‐
cytomegalovirus	activity	
#	3.		 Evaluate	 the	 potential	 clinical	 benefits	 of	 the	 anti‐cytomegalovirus	 activity	 of	
statins	alone	and	in	combination	with	ganciclovir	
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 Materials	and	Methods	
1. Cells		
Primary	 human	 aortic	 endothelial	 cells	 (HAEC,	 Lonza®	 CC‐2535)	 and	 cardiac	
microvascular	endothelial	cells	(HMVEC‐C,	Lonza®	CC‐7030)	were	respectively	used	at	
passages	9	to	14	and	5	to	10,	and	were	cultured	in	EGM‐2	medium	(Lonza)	following	the	
manufacturer’s	instructions.		
The	 human	 fetal	 lung	 fibroblast	 MRC‐5	 (ATCC®	 CCL‐171)	 at	 passages	 30	 to	 45	 were	
supplemented	 in	 Dulbecco's	 Modified	 Eagle	 Medium	 (DMEM,	 Invitrogen)	 containing	
10%	fetal	calf	serum	(FCS,	PAA	laboratories	ltd)	and	2	mM	L‐glutamine	(Invitrogen).		
All	 cell	 preparations	 were	 tested	 negative	 for	 mycoplasmas	 by	 4,6‐diamidino‐2‐
phenylindole	staining	(DAPI;	Sigma).		
2. Viruses	
The	HCMV	endotheliotropic	TB40/E	and	fibrotropic	TB40/F	strains	were	derived	from	a	
bone‐marrow	 transplant	 recipient	 by	 22	 passages	 in	 EC	 and	 fibroblasts,	 respectively	
[173].		
For	preparation	of	virus	stocks,	MRC‐5	were	infected	with	TB40/E	or	TB40/F	at	a	MOI	
of	0.5.	 Supernatants	of	 infected	cultures	were	harvested	at	7	days	post	 infection	 (dpi)	
and	 cleared	 of	 cellular	 debris	 by	 a	 10	 minute	 (min)	 centrifugation	 at	 2,500	 g.	 Virus	
stocks	were	partially	purified	by	an	ultracentrifugation	step	over	a	15%	sucrose	cushion	
(50mM	Tris‐HCl,	12mM	KCl,	5mM	Na2EDTA)	at	20,000	rpm	for	90	min	at	4°C	using	a	SS‐
34	rotor	(Beckman	Coulter).	Virus	aliquots	were	stored	at	‐80°C.	The	infectious	titer	was	
determined	by	the	Tissue	Culture	Infective	Dose	50	(TCID50)	assays	(see	below)	in	MRC‐
5	seeded	in	96‐well	plates	[174].	All	virus	preparations	were	tested	for	mycoplasmas	by	
DAPI	staining.	
	The	GCV‐resistant	strain	pp6,	derived	from	an	AIDS	patient	and	characterized	with	both	
M460I	 and	M460V	mutations	of	 the	UL97	gene	was	kindly	provided	by	K.	Hamprecht	
[175].		 	
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3. Reagents		
Stock	 solutions	 of	 atorvastatin	 calcium	 salt	 (Molekula),	 fluvastatin	 sodium	 salt	
(Calbiochem),	 simvastatin	and	pravastatin	 sodium	salt	 (Sigma)	were	done	 in	dimethyl	
sulfoxide	(Sigma).	Mevalonolactone	and	geranylgeranyl	pyrophosphate	ammonium	salt	
(Sigma)	were	dissolved	in	ethanol	and	methanol,	respectively.	Water	soluble	cholesterol,	
methyl	beta	cyclodextrin	(Sigma)	and	ganciclovir	(Cymevene®;	Roche)	were	dissolved	in	
water.	IFN‐α	was	purchased	from	Peprotech.	
All	stock	solutions	were	stored	according	to	manufacturer’s	specification	until	use.	Drug	
dilutions	 were	 prepared	 extemporaneously	 in	 culture	 medium.	 Except	 for	 statins,	 all	
reagents	were	assessed	by	trypan	blue	exclusion	and	alamarBlue®	assay,	respectively,	
and	used	at	subtoxic	doses	(data	not	shown).	The	final	concentrations	of	all	vehicles	in	
media	never	exceeded	0.1%	(v/v)	and	did	not	show	any	alteration	of	cell	viability	or	cell	
proliferation.		
Special	precautions	were	taken	to	avoid	exposure	of	statins	to	 light,	before	and	during	
incubation	procedures.	
4. Treatment	and	infection	
For	 all	 experiments,	 cells	 were	 seeded	 at	 25,000	 cells/cm2	 for	 HAEC	 and	 50,000	
cells/cm2	 for	MRC‐5	 in	 fresh	 culture	medium	 in	 order	 to	 reach	 cell	 confluence	 at	 the	
time	of	treatment.	Confluent	monolayers	were	treated	with	statins	and	other	drugs	24	
hours	 prior	 to	 infection,	 except	 if	 specified	 otherwise.	 GCV	 was	 added	 2	 hours	 post	
infection.	
To	infect	cells,	medium	was	removed	and	put	aside.	Cells	were	washed	with	Dulbecco's	
Phosphate	Buffer	 Saline	 (PBS,	 Lonza)	 and	 inoculated	with	 virus	diluted	 in	RPMI	1640	
(Invitrogen)	at	the	indicated	MOI	for	90	min	at	37°C.	After	inoculation,	the	virus	dilution	
was	removed,	cells	were	washed	with	PBS	and	replaced	by	 the	original	medium.	Cells	
were	kept	in	culture	with	drug‐containing	medium	for	the	corresponding	time.		
5. Cell	proliferation	assay	
Doses	 of	 statins	 used	 for	 this	 study	 were	 defined	 based	 on	 their	 anti‐proliferative	
activity	determined	using	the	alamarBlue®	assay	(Invitrogen).	Briefly,	cells	were	plated	
in	96‐well	plates	 in	triplicate	at	2,000	cells	per	well	and	4,000	cells	per	well	 for	HAEC	
and	MRC‐5,	respectively.	Cells	were	exposed	to	serially	diluted	concentrations	of	statins	
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ranging	 from	 0	 to	 1,000	 µM,	 for	 a	 72‐hour	 incubation.	 Every	 day,	 the	 cell	 viability	
reagent	was	added	to	respective	wells	and	absorbance	at	570	nm	was	determined	using	
a	 Victor2	 Multilabel	 Plate	 Reader	 (Wallac,	 PerkinElmer)	 after	 a	 4‐hour	 incubation	 at	
37°C.		
6. Tissue	Culture	Infective	Dose	50		assay	
HCMV	titers	were	determined	in	supernatants	of	infected	cultures	by	the	TCID50	assay.	
Briefly,	supernatants	were	harvested	and	cleared	of	cellular	debris	by	centrifugation	for	
10	min	at	2,500g,	aliquoted	and	stored	at	‐80°C.	The	infectious	titer	of	each	supernatant	
was	 determined	 in	 duplicate	 using	 distinct	 aliquots.	 Serial	 dilutions	 of	 supernatants	
were	used	in	quadruplicates	to	infect	96‐well	plates	of	MRC‐5	for	a	24‐hour	period.	Cells	
were	then	fixed	with	80%	acetone	(Sigma)	and	stained	with	antibodies	directed	against	
the	 IE	 proteins	 IE72	 and	 IE86	 (pUL122/123;	 mouse‐anti‐human	 E13,	 Argene)	 and	
detected	 with	 the	 Cy3‐conjugated	 secondary	 goat	 anti‐mouse‐IgG	 Fab’2	 (Jackson	
ImmunoResearch).	 Stained	 cultures	 were	 examined	 for	 IE‐positive	 cells	 with	 the	
fluorescent	 IX71	microscope	 (Olympus).	 Each	well	 containing	 at	 least	 one	 IE‐positive	
cell	was	defined	as	an	infected	culture.	Infectious	titers	were	calculated	as	described	by	
Mahy	&	Kangro		and	expressed	in	TCID50	mL‐1.		
7. qRT‐PCR		
Following	isolation	from	cells	and	supernatants	using	Qiagen	DNeasy	Blood	&	Tissue	Kit	
(Qiagen),	HCMV	DNA	was	amplified	and	quantified	using	specific	primers	and	probes	for	
a	62	bp	 region	of	 the	glycoprotein	B	gene	 (UL55)	 as	previously	described	 [176].	DNA	
quantification	was	performed	 in	duplicate	 in	a	 total	volume	of	30	µL	containing	10	µL	
DNA	and	using	HotStarTaq	master	mix	(Qiagen)	supplemented	with	PCR	primers	(1	µM	
each)	and	probes	(0.3	µM)	and	additional	MgCl2	(1.5	µM).	Amplification	was	performed	
in	a	Real‐Time	thermocycler	(iQ5	Cycler;	Bio‐Rad)	as	follows:	13min	30s	at	95°C	and	50	
cycles	of	15s	at	95°C	and	60s	at	60°C.	
8. Western	blot	analysis	
For	immunoblotting,	protein	samples	were	prepared	by	lysis	of	infected	cultures	grown	
in	24	or	12‐well	plates	in	sodium	dodecyl	sulphate	(SDS)	sample	buffer	(50	mM	tris–HCl,	
pH	6.8,	10%	glycerol,	2%	SDS,	10%	β‐mercapto‐ethanol,	and	0.1%	bromophenol	dye).	
Protein	 samples	 were	 separated	 by	 electrophoresis	 on	 a	 10%	 polyacrilamide	 gel,	
transferred	to	a	polyvinylidene	difluoride	membrane	(Hybond‐P,	GE	Healthcare).	After	
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blocking	 with	 5%	 non‐fat	 dried	 milk	 (Bio‐Rad)	 in	 2%	 tween/tris	 buffer	 saline,	
membranes	were	incubated	overnight	with	primary	antibody	at	4°C,	extensively	washed	
with	 2%	 tween/tris	 buffer	 saline	 and	 followed	 by	 a	 1‐hour	 incubation	 with	 a	
horseradish	 peroxidase‐conjugated	 secondary	 antibody	 (GE	Healthcare,	 1/5,000).	 The	
targeted	 proteins	 were	 revealed	 by	 enhanced	 chemiluminescence	 using	 the	 ECLTM	
western	blotting	detection	reagents	(GE	Healthcare).	
The	 following	primary	antibodies	were	used	 in	 this	study:	mouse	anti‐CMV	IE72/IE86	
(clone	 E13,	 Argene),	mouse	 anti‐CMV	pp52	 (clone	 10D8,	 Virusys	 corporation),	mouse	
anti‐CMV	pp65	 (Virostat),	mouse	 anti‐human	β‐actin	 (clone	AC‐15,	 Sigma)	 and	mouse	
monoclonal	anti‐myxovirus	protein	A	antibody,	kindly	provided	by	J.	Pavlovic	[177].	
9. Cellular	cholesterol	quantification	
For	 cellular	 cholesterol	 quantification,	 cell	 extract	 samples	 were	 prepared	 by	 lysis	 of	
cultures	grown	in	12‐well	plates.	Special	attention	was	given	to	determine	a	proper	lysis	
buffer	 (50mM	Tris,	 2mM	 CaCl2,	 80mM	NaCl,	 1%	 Triton	 X‐100)	 compatible	with	 both	
cholesterol	 and	 protein	 quantification	 methods.	 Cholesterol	 quantification	 was	
performed	 using	 the	 Amplex®	 Red	 Cholesterol	 Assay	 Kit	 (Invitrogen),	 a	 sensitive	
fluometric	method	 allowing	 the	 quantification	 of	 cholesterol	 and	 cholesterol	 ester	 by	
using	a	cholesterol	standard	curve.	A	total	protein	quantification	was	performed	using	
the	Pierce	Bicinchoninic	Acid	(BCA)	Protein	Assay	Kit	(Thermo	scientific),	a	detergent‐
compatible	 colorimetric	 method	 using	 an	 albumin	 standard	 curve	 for	 quantitation	 of	
total	 protein.	 Both	 assays	 were	 performed	 in	 96	 well	 microplate	 and	 read	 using	 the	
Synergy	2	multi‐mode	reader	(Biotek).	
Every	sample	was	quantified	 in	duplicate	 for	cholesterol	 content	and	normalized	with	
protein	concentration.		
10. Flow	cytometry	analysis	
Cells	 grown	 in	 6‐well	 plates	 (200,000	 cells/well)	were	 incubated	 for	5	min	with	PBS‐
2nM	 EDTA,	 washed	 and	 stained	 for	 30	min	 at	 4°C	 with	 PE,	 APC	 or	 Alexa	 Fluor	 488‐
conjugated	monoclonal	antibody	(mAb)	to	PDGFR,	1	integrins	and	EGFR,	respectively.	
The	 PE	 or	 APC‐conjugated	 MOPC21	 (BD	 Pharmingen)	 and	 the	 Alexa	 Fluor	 488	
conjugated	normal	mouse	 IgG	 (Millipore)	were	used	as	 isotype‐matched	 controls.	The	
fluorescence	 intensity	 was	 measured	 by	 using	 a	 FACSCanto	 (BD	 Biosciences)	 and	
analysis	was	performed	using	FlowJo	software	(Tree	Star).	
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The	following	primary	antibodies	were	used	in	this	study:	APC	conjugated	mouse	anti‐
1	 integrins	 (Thermo	 Scientific	 for	 flow	 cytometry,	 clone	MEM‐101A),	mouse	 anti‐V	
integrin	(Santa	Cruz,	clone	P2W7)	and	mouse	anti‐3	integrin	(Santa	Cruz,	clone	BV4),	
PE	conjugated	mouse	anti‐	PDGFR	(Santa	Cruz	clone	16A1	for	flow	cytometry),	AF488	
conjugated	mouse	anti‐EGFR	(Millipore	for	flow	cytometry,	clone	LA1)	
11. Cell	cycle	progression	analysis	
Cells	 seeded	 in	6‐well	plates	 (200,000	 cells/well)	 in	 serum‐free	medium	were	 treated	
for	1	or	4	days	with	statins	at	37°C.	Cells	were	then	trypsinized,	washed	twice	with	cold	
PBS	 by	 resuspending	 and	 spinning	 down	 (2,000	 rpm,	 5min).	 After	 the	 last	
centrifugation,	 supernatant	 was	 discarded	 and	 cells	 were	 fixed	 with	 70%	 ice‐cold	
ethanol	 and	 incubated	overnight	at	4°C.	The	next	day,	 cells	were	 centrifuged	5	min	at	
3,000	rpm,	the	pellet	was	stained	for	30	min	at	37°C	in	the	dark	under	gentle	shacking	
with	 a	 staining	 solution	 (PBS,	 0.3mg/ml	 of	 RNAseA,	 0.3mg/ml	 of	 propidium	 iodide).	
After	centrifugation	(5	min,	3,000	rpm)	cells	were	resuspended	in	100l	of	the	staining	
solution	 and	 analyzed	 by	 flow	 cytometry	within	 24	 hours.	 The	 fluorescence	 intensity	
was	 measured	 by	 using	 a	 FACS	 Canto	 (BD	 Biosciences)	 and	 analysis	 was	 performed	
using	FlowJo	software	(Tree	Star).	
12. Statistical	Analysis	
All	values	are	reported	as	mean	values	±	SD,	the	number	of	experiments	is	specified	in	
the	 figure	 legends	 section.	 Statistical	 comparisons	 between	 experimental	 conditions	
were	 performed	 with	 the	 Stat	 View	 (V5.0.1)	 software	 using	 the	 analysis	 of	 variance	
followed	 by	 Fisher’s	 exact	 test	 with	 statistically	 significant	 differences	 set	 as:	 *p	 <	
0.05,**p	<	0.01,***p	<	0.001.		
Fifty	percent	and	ninety	percent	effective	dose	(ED50,	ED90)	values	were	calculated	using	
nonlinear	regression	curve	fit	with	a	variable	slope.	GraphPad	Prism	5.04	software	was	
used	for	all	analyses.	
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 Results	
I. Statins	exert	an	anti‐cytomegalovirus	activity	
in	aortic	endothelial	cells	
1. Anti‐proliferative	activity	of	statins	on	HAEC	
Besides	a	shared	HMG‐like	moiety	allowing	the	competitive	 inhibition	of	the	HMG‐CoA	
reductase,	statins	differ	in	their	potency	for	mevalonic	acid	synthesis	inhibition	mainly	
because	of	large	differences	of	solubility,	tissue	permeability	and	metabolism,	related	to	
their	chemical	structures	[147].		
In	order	to	compare	the	effect	of	four	chemically‐different	statins	on	HCMV	replication,	
we	defined	3	doses	 for	each	of	 the	 statins:	 the	 IC50,	 IC20	 and	 sub‐inhibitory	dose	 (SD),	
being	 the	 concentrations	 responsible	 for	 50%,	 20%	 or	 no	 cell	 growth	 inhibition,	
respectively,	 as	 compared	 with	 untreated	 control	 cell	 growth.	 Increasing	 doses	 of	
atorva‐,	 fluva‐,	 prava‐	 and	 simvastatin	 ranging	 from	0	 to	1,000	µM	were	 added	 to	 the	
cells	24	hours	post	seeding.	Cell	proliferation	was	quantified	every	24	hours	within	a	72‐
hour	period	of	time	in	an	alamarBlue®	assay.	
	
Figure	8:	Anti‐proliferative	activity	of	statins	in	HAEC	after	a	72‐hour	drug	
exposure	period.	
Scatter	plots	of	the	statins	concentrations	responsible	for	50%	(IC50),	20%	(IC20)	or	no	cell	
growth	inhibition	(SD)	as	compared	with	untreated	culture.	Bar	represent	mean	±	SEM	of	at	
least	3	experiments.		
Whereas	atorva‐,	fluva‐	and	simvastatin	exhibited	a	fairly	comparable	toxicity	on	HAEC,	
pravastatin	 was	 drastically	 less	 toxic	 (Figure	 8).	 The	 SD	 of	 atorva‐,	 fluva‐	 and	
simvastatin	were	between	0.02	and	0.1	µM	whereas	 it	 reached	50	μM	 for	pravastatin.	
The	IC20	of	atorva‐,	fluva‐	and	simvastatin	were	in	the	low	micromolar	range,	fluvastatin	
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being	 the	 most	 potent	 in	 inhibiting	 HAEC	 proliferation	 (0.07	 μM),	 followed	 by	
simvastatin	 (0.3	 μM)	 and	 atorvastatin	 (0.4	 μM).	 In	 contrast	 pravastatin	 exhibited	 a	
limited	anti‐proliferative	activity	(120	μM).	For	the	4	statins,	the	IC50	were	2	to	5	times	
higher	to	IC20.		
In	all	further	experiments,	the	concentrations	as	reported	in	Table	3	were	used	to	treat	
HAEC	and	alamarBlue®	assays	were	performed	in	parallel	to	ensure	proper	drug	effects	
of	the	IC50,	IC20	and	SD	on	proliferation.		
2. All	statins	exhibit	an	effective	anti‐cytomegalovirus	
activity	
To	evaluate	the	anti‐CMV	activity	of	statins,	HAEC	were	treated	with	the	3	doses	of	each	
statin	24	hours	prior	to	HCMV	infection	at	an	MOI	of	1.	HCMV	titers	were	determined	at	
6	 dpi	 in	 the	 supernatants	 of	 cultures	 by	 a	 TCID50	 assay.	 Figure	 9	 reveals	 a	 dose	
dependent	anti‐CMV	activity	exerted	by	all	four	statins.	
	
Figure	9:	Statins	dose‐dependently	inhibit	HCMV	infectious	titers	in	HAEC.	
HCMV	infectious	titers	were	determined	in	supernatant	of	cultures	at	6	dpi	by	a	TCID50	
assay.	Results	are	expressed	in	TCID50	mL‐1	as	mean	values	±	SD	of	five	independent	
experiments.	
At	 the	 SD,	 atorva‐	 and	 simvastatin	 significantly	 reduced	 the	 titers	 by	 0.4	 and	 0.5	 log	
respectively;	pravastatin	decreased	the	titer	by	1	log	whereas	fluvastatin	had	no	effect.	
At	 the	 IC20	 and	 the	 IC50,	 all	 statins	 significantly	 impacted	HCMV	 titers	with	 fluvastatin	
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exhibiting	the	most	limited	effect.	At	the	IC50,	HCMV	titer	reduction	reached	2.4	log	for	
simvastatin,	2.8	log	for	atorvastatin	and	3	log	for	pravastatin.		
Table	3:	In	vitro	anti‐proliferative	and	anti‐CMV	activity	of	statins	on	HAEC.	
Cell type Drug 
Anti-proliferative activitya (μM) Anti-CMV activityb (μM) 
SD IC20 IC50 EC50 EC90 
HAEC 
Atorvastatin 0.01 0.5 2 0.03 ± 0.05 0.17 ± 0.10 
Fluvastatin 0.01 0.1 0.3 0.03 ± 0.03 0.31 ± 0.18 
Pravastatin 50 100 400 26 ± 8 64 ± 20 
Simvastatin 0.01 0.5 1 0.003 ± 0.006 0.1 ± 0.08 
a Concentrations responsible for 50% (IC50), 20% (IC20) or no cell growth inhibition (SD or sub-
inhibitory dose) over a 72-hour period of time, as compared with untreated control cell growth. 
b EC50 and EC90 values determined by TCID50 assay. Nonlinear regression analysis was performed, 
and the resulting graphs were used to calculate the respective values. Results are expressed as means ± 
standard deviations of at least 3 independent experiments. 
 
To	compare	the	potential	of	the	four	statins	to	inhibit	HCMV	replication,	independently	
of	 their	 anti‐proliferative	 activity,	 we	 determined	 the	 effective	 concentration	 50	 %	
(EC50)	and	90	%	(EC90),	being	the	concentration	of	product	at	which	virus	replication	is	
inhibited	by	50	and	90	percent.	EC50	and	EC90	were	found	to	be	within	the	concentration	
range	 of	 the	 SD	 and	 IC20	 used	 (Table	 3).	 Simvastatin	 exhibited	 the	 highest	 inhibitory	
potency	(EC50~3	nM)	as	compare	to	atorva‐	and	fluvastin	(EC50~30	nM),	although	they	
all	 displayed	 a	 similar	 EC90	 between	 0.1	 µM	 and	 0.3	 µM.	 In	 contrast,	 the	 inhibitory	
potency	of	pravastatin	was	drastically	lower	(EC50~26	µM).		
3. Increasing	multiplicity	of	infection	do	not	affect	the	
anti‐cytomegalovirus	activity	of	statins	
Liu	 et	 al.	 demonstrated	 that	 the	 reduction	 of	 poliovirus	 infection,	 resulting	 from	 a	
disruption	of	 cholesterol‐rich	domains	 by	methyl‐β‐cyclodextin	 (MβCD),	was	 reversed	
by	an	increasing	MOI	[150].			
Similarly,	we	evaluated	the	MOI	dependency	of	the	anti‐CMV	activity	of	statins.	Atorva‐	
and	simvastatin,	resulting	in	a	similar	impact	on	HCMV	titers	than	pravastatin	but	with	
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much	 lower	 concentrations,	 were	 both	 used	 to	 treat	 HAEC	 with	 the	 IC50	 before	 the	
inoculation	 with	 MOI	 ranging	 from	 0.03	 to	 10	 (Figure	 10).	 The	 infectious	 titers	
measured	in	supernatants	of	control	cultures	at	6	dpi	increased	from	2	log	TCID50	mL‐1	
at	an	MOI	of	0.03,	up	to	6	log	TCID50	mL‐1	at	an	MOI	of	10.	No	infectious	progenies	were	
detected	in	supernatants	of	cultures	treated	with	statins	and	infected	at	an	MOI	≤	0.3,	as	
compared	 to	 untreated	 cultures.	 Consistently,	 at	 an	 MOI	 ≥	 1,	 both	 statins	 exhibited	
similar	effects	and	stably	reduced	HCMV	titers	by	almost	3	 log	as	compared	to	control	
cultures),	 suggesting	 that	 statin	 potency	 is	 sufficient	 to	 encounter	 with	 high‐MOI	
infections.		
	
Figure	10:	Influence	of	the	multiplicity	of	infection	on	the	anti‐cytomegalovirus	
activity	of	statins	in	HAEC.	
Statin‐treated	cultures	were	inoculated	with	HCMV	at	MOI	ranging	from	0.03	to	10.	HCMV	
infectious	titers,	determined	in	supernatant	of	cultures	at	6	dpi,	are	expressed	in											
TCID50	mL‐1.	One	representative	experiment	out	of	two	is	shown.	
Although	 the	 four	 statins	we	 tested	 differ	 in	 their	 chemical	 structures,	 their	 ability	 to	
lower	cholesterol	in	vivo	[130]	or	to	inhibit	cell	proliferation	in	vitro,	we	confirmed	the	
anti‐CMV	activity	of	fluvastatin	even	at	lower	doses	than	previously	demonstrated	[163]	
and	that	 this	effect	 is	not	 limited	to	a	specific	statin.	Furthermore,	all	 lipophilic	statins	
we	tested	manifest	a	potent	anti‐CMV	activity	using	doses	in	a	similar	micromolar	range.	
On	 the	 other	 hand,	 although	 pravastatin	 displayed	 the	 strongest	 ability	 to	 reduced	
HCMV	infectious	titers,	the	in	vitro	concentrations	to	achieve	such	anti‐CMV	effect	might	
limit	the	existence	of	a	similar	activity	in	vivo.	
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II. Cellular	and	molecular	mechanisms	of	
the	anti‐cytomegalovirus	activity	of	statins	in	
endothelial	cells	
Endothelial	 cells	 are	 assumed	 to	 play	 a	 central	 role	 in	 the	 haematogeneous	
dissemination	of	HCMV	through	the	productive	infection	of	the	vascular	endothelium	in	
vivo,	with	 virus	 being	 very	 likely	 to	 spread	 from	EC	by	 release	 into	 the	 blood	 stream,	
contact	with	adjacent	cells	or	transiently	adhering	leukocytes	[178].	
In	the	meantime,	the	protective	barrier	formed	by	vascular	EC	between	circulating	blood	
and	 the	 rest	 of	 the	 blood	 vessel	 wall	 is	 directly	 exposed	 to	 statins	 via	 the	 blood	
circulation	 and	was	 shown	 to	 be	 one	 of	 the	 key	mediators	 of	 their	 pleiotropic	 effects	
[134].	 In	vitro,	 several	 cellular	 functions	 of	EC	were	 shown	 to	 be	modulated	by	 statin	
treatment.	Atorva‐,	fluva‐	and	simvastatin	have	pro‐apoptotic	effect	by	down‐regulating	
Bcl‐2	expression	[179].	Simvastatin	disorganizes	the	actin	cytoskeleton	of	activated	EC	
[180].	 Moreover,	 both	 atorva‐	 and	 simvastatin	 downregulate	 the	 activation	 of	 pro‐
inflammatory	 transcription	 factor	 NF‐κB	 [181].	 All	 these	 cellular	 functions,	 among	
others,	are	required	 for	 the	HCMV	entry	and	replication	and	could	thus	be	 involved	 in	
the	mechanism	of	the	anti‐CMV	activity	of	statins.	
To	 identify	 the	mechanism	of	 the	anti‐CMV	activity	of	 statins,	we	 looked	 for	 effects	of	
statins	on	EC	phenotypes.	In	a	second	time,	we	investigated	in	detail	the	different	steps	
of	the	HCMV	replication	cycle.		
1. Effects	of	statin	treatment	on	cell	phenotypes	
1.1 Statin	treatment	does	not	result	in	cellular	cholesterol	
depletion	
In	fibroblasts,	disruption	of	 lipid	rafts	by	depletion	of	cellular	cholesterol	 inhibits	both	
HCMV	 entry	 and	 IFN	 responses	 [182].	 The	 first	 and	main	 role	 of	 statins	 in	 vivo	 is	 to	
lower	blood	cholesterol	 levels.	In	vitro,	pravastatin	treatment	was	shown	to	result	 in	a	
dose‐dependent	inhibition	of	macrophage	cholesterol	[183].		
To	assess	whether	statin	treatment	resulted	into	a	disruption	of	the	cellular	cholesterol	
in	HAEC	over	the	period	of	infection,	we	determined	the	cholesterol	content	into	the	cell	
extract	 of	 cultures	 treated	 with	 statins,	 using	 the	 Amplex®	 Red	 cholesterol	 assay.	 A	
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cholesterol‐protein	 ratio	 was	 determined	 for	 all	 conditions	 to	 exclude	 any	 variability	
due	 to	 the	 cellular	 concentration.	 A	 1‐hour	 treatment	 with	 MβCD	 (10mM),	 a	 known	
cholesterol	depleting	reagent,	was	used	as	a	positive	control	for	each	time	point.		
Over	a	period	of	7	days	of	treatment,	no	significant	and	reproducible	modulation	of	the	
cellular	 levels	 of	 cholesterol	 was	 observed	 between	 statin‐treated	 and	 untreated	
cultures	up	to	4	days.	At	5	and	6	days	post	treatment,	an	increase	of	the	cholesterol	level	
could	be	observed	in	some	of	the	statin‐treated	cultures.	Nevertheless,	these	variations	
were	 inconsistent	 over	 repeated	 experiments	 and	 the	 co‐treatment	 with	 mevalonate	
(MVA)	 never	 counteracted	 theses	 variations,	 suggesting	 an	 unspecific	 effect	 (data	 not	
shown).	
No	 significant	 modulation	 of	 the	 cellular	 cholesterol	 level	 was	 observed	 in	 HAEC	
following	 treatment	 with	 statin	 that	 could	 be	 correlated	 with	 an	 inhibition	 of	 HCMV	
entry	after	1	day	of	treatment	or	an	 inhibition	of	the	virus	egress	after	several	days	of	
treatment.	
1.2 Statins	modulate	HCMV	entry	receptor	expression	
HCMV	 use	 several	 trans‐membrane	 protein	 receptors	 to	 enter	 into	 cells,	 including	
EGFRand	PDGFRα	or	co‐receptors	such	as	αvβ3	integrin	or	β1	integrin	subunit.	[14‐16,	
184].	Statins	were	shown	to	modulate	their	expressions.	Atorvastatin	increases	the	cell	
surface	expression	of	α2β1	 integrin	on	vascular	smooth	muscle	cells,	and	 lovastatin	to	
downregulate	EGFR	expression	[185,	186].		
We	 therefore	 analyzed	HAEC	 for	 their	 relative	 cell	 surface	 expression	 of	 HCMV	 entry	
receptors	 and	 co‐receptors	 after	 a	 24‐hour	 treatment	 with	 the	 statins’	 IC50.	 Surface	
expression	of	EGFR,	PDGFRα	and	β1	 integrins	was	quantified	by	 flow	cytometry.	High	
level	of	β1	 integrins	and	 low	 levels	of	PDGFRα	were	detected	on	non‐treated	cultures	
but	no	EGFR	expression	(Figure	11).	All	statins	increase	the	cell	surface	expression	of	β1	
integrins	by	27%	up	to	65%	with	atorva‐	and	pravastatin,	respectively.	In	comparison,	
only	prava‐	and	simvastatin	did	increased	PDGFRα	cell	surface	expression	but	only	in	a	
very	limited	manner.		
Therefore,	the	modulation	of	HCMV	entry	receptors	we	observed	at	the	time	of	infection	
rather	suggests	a	possible	increase	than	an	inhibition	of	HCMV	entry	that	could	explain	
the	anti‐CMV	activity	of	statins.	
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Figure	11:	Effect	of	a	24‐hour	statin	treatment	on	the	cell	surface	expression	of	
HCMV	entry	receptors	on	HAEC.	
Histograms	overlays	of	anti‐entry	receptor	staining	(blue)	versus	isotype	control	(grey),	
median	fluorescence	intensity	ratio	are	indicated.	
	
1.3 Statins	do	not	induce	a	cell	cycle	arrest	in	EC	
A	pilot	 study	 showed	 that	murine	3T3	cells	maintained	 in	 the	G1	phase	permit	HCMV	
replication	 [187].	 Moreover,	 inhibition	 of	 cyclin‐dependent	 kinase	 2	 (Cdk2)	 activity,	
which	 regulates	 cell	 cycle	 progression	 in	 G1	 and	 S	 phase	 activity	 blocks	 HCMV	
replication,	indicating	that	activation	of	cellular	Cdk2	is	necessary	for	HCMV	replication	
[188].	 Interestingly,	cell	cycle	analysis	of	vascular	EC	reveals	 that	24‐hour	exposure	to	
fluvastatin	prevents	cells	 from	leaving	G1	[189].	Simvastatin	also	causes	a	G1	arrest	 in	
different	types	of	human	melanoma	cell	lines	[190].	Mevastatin	inhibits	cdk2	activity	in	
PC3	cells	through	the	inhibition	of	Thr‐160	phosphorylation	of	cdk2	[191].		
We	thus	decided	to	examine	the	effect	of	all	four	statins	on	the	cell	cycle	progression	of	
HAEC.	Cells,	seeded	in	similar	conditions	as	for	infection	experiments,	were	treated	with	
the	statin	IC50,	 fixed	after	1	or	4	days	of	 treatment,	stained	with	propidium	iodide	and	
analyzed	 by	 flow	 cytometry.	 DMSO	 and	 nocodazole	were	 used	 as	 a	 G1	 and	 G2	 arrest	
control,	 respectively.	 After	 1	 day	 of	 treatment,	 the	 percentage	 of	 cells	 determined	 for	
each	 phase	 of	 the	 cell	 cycle	 revealed	 a	 large	majority	 of	 cells	 in	 G1	 in	 the	 untreated	
cultures	 (80%)	 and	 only	 a	 small	 fraction	 in	 the	 G2/M	 phase	 (10%).	 While	 DMSO	
increased	the	fraction	of	cells	in	G1	(84%)	and	nocodazole	treatment	resulted	in	a	large	
shift	 of	 cells	 in	 the	 G2/M	 phase	 (30%),	 none	 of	 the	 statins	were	 able	 to	 significantly	
modulate	 the	 cell	 cycle	progression	 (Figure	12).	 Similar	 results	were	observed	after	4	
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days	of	treatment	(data	not	shown).	In	another	set	of	experiments,	although	lower	cell‐
seeding	 concentration	 were	 used	 to	 delay	 the	 confluency	 of	 cells	 and	 therefore	 a	 G1	
arrest,	no	significant	modulation	of	the	cell	cycle	progression	was	observed	with	statin	
treatment	in	our	hands.	
	
	
Figure	12:	Effect	of	a	24‐hour	statin	treatment	on	the	cell	cycle	progression	of	
HAEC.	
Cell	cycle	analysis	of	cultures	treated	for	24	hours	with	DMSO,	nocodazole	or	the	statin	IC50.	
Histograms	overlays	of	cells	in	G1	(green)	and	G2/M	(blue)	phases	are	indicated.	
	
Using	 similar	 conditions	 for	 all	 our	 experiments,	 it	 is	 thus	 unlikely	 that	 statins	 exert	
their	anti‐CMV	activity	through	an	effect	on	the	cell	cycle	progression	since	the	majority	
of	the	cells	already	are	in	the	G1	phase	required	for	HCMV	replication.	
	
1.4 Statins	do	not	stimulate	the	type	I	interferon	pathway	
Type	I	IFN	is	one	of	the	most	important	effector	cytokine	inhibiting	viral	replication	by	
inducing	host	genes	expression	[192,	193].	In	vitro,	pre‐treatment	of	human	fibroblasts	
with	 IFN‐α	 or	 IFN‐β	 was	 shown	 to	 inhibit	 HCMV	 plaque	 formation	 [194].	 Moreover,	
disruption	 of	 lipid	 rafts	 by	 cholesterol	 depletion	 using	 MβCD	 interferes	 with	 the	
induction	 of	 the	 IFN	 response	 to	 HCMV	 infection	 [182].	 We	 wondered	 whether	 the	
reduced	HCMV	titers	observed	upon	statin	treatment	might	result	from	an	activation	of	
the	type	I	IFN	pathway	by	statins.		
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Figure	13:	MxA	expression	in	statin‐treated	cultures	of	HAEC.	
Western	blot	analysis	of	the	myxovirus	protein	A	expression	in	cultures	treated	for	24	hours	
with	the	statin	IC50	or	with	1000	unit/mL	IFN‐	α.	β‐actin	was	used	as	a	loading	control.	One	
representative	experiment	out	of	three	is	shown.	
	
To	this	end,	we	analyzed	expression	of	the	myxovirus	protein	A	(MxA),	an	IFN‐inducible	
antiviral	 effector,	 after	 a	 24‐hour	 treatment	 either	 with	 the	 statin	 IC50	 or	 with	 1,000	
unit/mL	 IFN‐α	 used	 as	 positive	 control	 (Figure	 13).	 Compared	 to	 untreated	 cultures,	
HAEC	treated	with	IFN‐α	exhibited	a	markedly	increased	expression	of	MxA.	Inversely,	
MxA	 expression	was	 not	 affected	 by	 statin	 treatment.	 Thus,	 statins	 do	 not	 exert	 their	
anti‐CMV	 activity	 by	 targeting	 the	 pathway	 of	 the	 immediate	 host	 response	 to	 virus	
infection.	
	
2. Effects	of	statins	treatment	on	HCMV	replication	cycle	
In	 the	 absence	 of	 any	 identifiable	 cellular	 function	 specifically	 affected	 by	 statin	
treatment	that	could	explain	the	mechanism	of	the	anti‐CMV	activity	of	statins,	we	next	
investigated	potential	targets	within	the	HCMV	replication	cycle.		
	
2.1 Statins	do	not	interfere	with	HCMV	entry	
To	determine	 if	 statin	 prevent	 viral	 attachment	 and/or	HCMV	entry	 into	 the	 cells,	we	
quantified	 the	 amount	 of	 viral	 DNA	 present	 in	 cell	 extracts	 of	 statin	 treated	 cultures	
shortly	after	the	start	of	the	infection	2	hpi	(Figure	14A).	No	differences	in	the	number	of	
viral	DNA	copies	were	observed	between	control	and	statin‐treated	cultures.		
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Figure	14:	Statins	do	not	interfere	with	HCMV	entry	in	HAEC.	
(A)	HCMV	DNA	copies	quantified	by	real	time‐PCR	in	the	cell	extract	(30	ng	of	total	DNA)	of	
HAEC	cultures	at	2	hpi.	One	representative	experiment	out	of	two	is	shown.		
(B)	HCMV	infectious	titers	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	cultures.	
Statin	IC50	were	added	i)	24	hours	prior	infection	and	kept	until	the	end	of	the	experiment	
(T‐24h	constant),	ii)	24	hours	prior	to	infection	and	definitively	remove	at	the	time	of	
infection	(T‐24h	removed),	iii)	6	hours	(T+6h	constant)	or	12	hours	(T+12h	constant)	after	
HCMV	infection	and	kept	until	the	end	of	the	experiment.	Results	are	expressed	in	relative	
level	of	infection	compared	to	untreated	cultures,	and	bars	represent	mean	values	±	SD	of	
two	independent	experiments.	
In	addition,	we	explored	the	effects	of	different	times	of	drug	treatment	relative	to	virus	
exposure	 (Figure	 14B).	 Statins	 were	 added	 at	 different	 time	 prior‐	 or	 post‐HCMV	
infection	and	were	co‐incubated	for	the	duration	of	the	culture	or	removed	at	the	time	of	
infection.	 At	 6	 dpi,	 supernatants	 were	 subjected	 to	 TCID50	 assay	 to	 determine	 HCMV	
titers.	When	HAEC	were	pre‐incubated	for	24	hours	with	statins	followed	by	removal	at	
the	time	of	infection,	titers	almost	recovered	to	the	level	of	drug‐free	cultures	(86%	for	
both	 atorva‐	 and	 simvastatin).	 Interestingly,	 no	 difference	 in	 the	 anti‐CMV	 activity	 of	
statins	 was	 observed	 between	 statin	 treatment	 starting	 from	 24	 hours	 prior	 HCMV	
infection	or	12	hours	after	HCMV	infection.	These	data	suggest	that	statins	interfere	with	
HCMV	replication	at	a	step	downstream	from	HCMV	entry.	
2.2 Statins	do	not	directly	reduce	virion	infectivity	but	reduce	
viral	DNA	production		
We	next	assessed	if	the	observed	reduction	in	HCMV	titers	was	due	to	a	decrease	in	the	
number	of	virions	produced	or	the	result	of	an	alteration	of	their	infectivity	or	stability.	
The	amount	of	viral	DNA	at	5	dpi	was	quantified	by	real	 time	PCR	in	the	supernatants	
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and	cell	extracts	of	HAEC	cultures	treated	with	the	IC50	of	the	respective	statins	(Figure	
15	 A&B).	 Compare	 to	 untreated	 cultures,	 treatment	 with	 all	 statins	 led	 to	 a	 marked	
reduction	in	the	number	of	viral	DNA	copies	in	the	supernatants,	although	limited	with	
fluvastatin.	Meanwhile,	 the	 intracellular	number	of	copies	was	equally	reduced,	except	
for	 fluvastatin‐treated	 cultures	 (Figure	 15B).	 These	 data	 suggest	 a	 blockade	 of	 HCMV	
replication,	occurring	after	HCMV	entry	 into	 the	cells	and	before	 the	virion	exocytosis,	
resulting	in	a	reduced	number	of	 infectious	virions	released	rather	than	a	reduction	of	
virion	infectious	potential.	
	
Figure	15:	Statins	do	not	interfere	with	viral	DNA	replication	in	HAEC.	
HCMV	DNA	copies	were	quantified	at	5	dpi	by	real	time‐PCR	in	(A)	100	μL	of	supernatant	
(SN)	and	(B)	in	the	cell	extract	(30	ng	of	total	DNA)	of	HAEC	cultures.	One	representative	
experiment	out	of	three	is	shown.	
	
2.3 Statins	prevent	viral	antigen	expression	
To	identify	the	stage	of	viral	replication	which	is	compromised	by	statin	treatment,	time‐
course	relative	expression	of	the	IE,	E	and	L	antigens	was	analyzed	from	1	to	6	dpi	by	
western	blotting	(Figure	16).	As	expected,	in	control	cultures	IE	antigens	were	observed	
from	 1	 dpi	 onwards	 and	 continuously	 accumulated	 up	 to	 6	 dpi,	 while	 both	 E	 and	 L	
antigens	were	detected	from	3	dpi	onwards.	Noteworthy,	in	statin‐treated	cultures,	only	
low	 amounts	 of	 IE	 antigens	were	 detected	 at	 1	 dpi	 and	 no	 further	 accumulation	was	
noticed	 after	 2	 dpi.	Moreover,	 neither	 E	 nor	 L	 antigens	were	 detected	 up	 to	 6	 dpi	 in	
cultures	treated	with	atorva‐,	prava‐	or	simvastatin.	
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Figure	16:	Statins	affects	the	expression	of	the	three	families	of	viral	antigens	in	
HAEC.	
Western	blot	analysis	of	viral	IE,	E	(pp52)	and	L	(pp65)	antigen	expression	between	1	and	6	
dpi	in	cultures	treated	with	the	statin	IC50.	β‐actin	was	used	as	a	loading	control.	One	
representative	experiment	out	of	three	is	shown.	
In	 order	 to	 exclude	 a	 specific	 inhibition	 of	 some	 antigens,	 we	 evaluated	 the	 effect	 of	
statins	on	others	viral	antigens	as	well.	The	expression	of	MCP,	another	late	antigen	was	
also	dramatically	 inhibited	in	cultures	treated	with	the	atorva‐,	prava‐	and	simvastatin	
IC20	at	6	dpi	(Figure	17).	
	
Figure	17:	MCP	expression	in	statin‐treated	cultures	of	HAEC.	
Western	blot	analysis	of	the	late	Major	Capsid	Protein	(MCP)	expression	at	6	dpi	in	cultures	
treated	with	the	statin	IC20.	β‐actin	was	used	as	a	loading	control.	One	representative	
experiment	out	of	three	is	shown.	
Consistent	with	its	limited	effect	on	HCMV	titers,	fluvastatin	treatment	only	moderately	
impacted	the	expression	of	 the	different	viral	antigens	as	compared	to	 the	 three	other	
statins.	Though	IE	expression	was	reduced	when	compared	to	untreated	control	culture,	
accumulation	of	IE	antigens	reoccurred	after	4	dpi	(Figure	16).	Consistently,	both	E	and	
L	 antigens	 increased	 at	 5	 dpi	 but	 the	 level	 of	 expression	 remained	 lower	 than	 their	
respective	controls	and	MCP	expression	was	only	slightly	reduced	at	6	dpi	(Figure	17).	
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This	 suggests	 a	 delay	 of	 3	 days	 in	 the	 initiation	 of	 the	 replication	 cycle	 induced	 by	
fluvastatin	 while	 other	 statins	 achieved	 a	 stable	 inhibition	 over	 the	 whole	 period	 of	
infection.	 This	 may	 also	 explain	 the	 previously	 observed	 high	 number	 of	 viral	 DNA	
copies	 in	the	cell	extract	but	not	 in	the	supernatant	of	 fluvastatin‐treated	cultures	at	5	
dpi	(Figure	15).	
Overall,	these	data	show	that	atorva‐,	prava‐	and	simvastatin	halted	the	accumulation	of	
IE	 antigens	 and	 abrogated	 post‐IE	 expression	 of	 viral	 gene	 products	 (early,	 early‐late	
and	 late).	 The	 limited	 impact	 of	 fluvastatin	 on	 virus	 titers	 coincided	with	 a	moderate	
delay	of	the	accumulation	of	IE,	E	and	L	gene	products.	
	
2.4 Statins	mainly	target	late	antigen	expression	
Since	 the	 3	 families	 of	 antigens	 are	 sequentially	 expressed	 and	 IE	 antigens	 acted	 as	
transcriptional	activators	for	the	E	genes,	we	wondered	whether	the	abrogation	of	post‐
IE	viral	gene	products	(early,	early‐late	and	late)	expression	by	statins	resulted	from	the	
inhibition	of	IE	expression	or	if	they	were	also	specifically	inhibited.		
To	 do	 so,	 HAEC	 cultures	were	 treated	with	 the	 statin	 IC50	 either	 24	 hours	 before	 the	
inoculation	 with	 HCMV	 (as	 for	 previous	 experiments)	 or	 at	 various	 times	 after	 the	
inoculation	 ranging	 from	 6	 to	 36	 hours	 post	 infection	 (hpi)	 (Figure	 18	 A‐C).	
Interestingly,	 the	 reduction	of	HCMV	 titer	 obtained	with	 a	pre‐infection	 treatment	 (T‐
24h)	was	maintained	when	treatment	was	delayed	up	to	18	hpi	with	simvastatin	and	24	
hpi	with	atorvastatin.	Not	only	does	that	confirm	the	statin	do	not	interfere	with	HCMV	
entry,	but	it	suggest	that	statins	do	not	only	affect	IE	antigens	expression.		
Indeed,	 the	expression	of	 IE	antigens	at	3dpi	disclosed	 that	only	cultures	 treated	with	
atorva‐	or	simvastatin	prior	to	infection	(T‐24h)	exhibit	a	notable	reduced	amount	of	IE	
antigens	 (Figure	 18	 B).	 In	 contrast,	 the	 inhibition	 of	 pp65	 expression	 at	 6	 dpi	 was	
maintained	in	cultures	treated	as	late	as	24	hpi	for	atorvastatin	but	only	up	to	6	hpi	for	
simvastatin,	 treatment	 at	 18	 and	 24	 hpi	 resulting	 in	 a	 partial	 inhibition	 only	 (Figure	
18C).	
Overall,	these	data	show	that	statins	halted	the	accumulation	of	post‐IE	antigens	(early,	
early‐late	and	late),	independently	of	the	inhibition	of	IE	antigens.		
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Figure	18:	The	anti‐CMV	activity	of	statins	in	HAEC	persists	up	to	a	24	hpi	delay	of	
treatment.		
HAEC	cultures	were	treated	with	the	atorva‐	or	simvastatin	IC50	at	various	time	points	from	
24	hours	prior	to	infection	(T‐24h)	up	to	36	hours	post	infection	(T+36h).	(A)	HCMV	
infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	cultures.	
Results	are	expressed	in	TCID50	mL‐1	as	mean	values	±	SD	of	two	independent	experiments.	
(B+C)	Western	blot	analysis	of	viral	IE	antigen	expression	at	3	dpi	(B)	and	L	antigen	at	6	dpi	
(C):	β‐actin	was	used	as	a	loading	control.	One	representative	experiment	out	of	three	is	
shown.	
2.5 Mevalonate‐derived	products	mediate	the	anti‐
cytomegalovirus	activity	of	statins	
To	get	more	insights	into	the	mechanism	of	the	anti‐CMV	activity	of	statins,	metabolite	
rescue	 experiments	 were	 conducted	 where	 mevalonate	 (MVA),	 geranylgeranyl	
pyrophosphate	 (GGPP)	 and	 cholesterol	 (CHO)	 were	 used	 to	 counteract	 the	 statin‐
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mediated	 effects.	 AlamarBlue®	 assays	were	 first	 conducted	 to	 evaluate	 the	 toxicity	 of	
each	 metabolite	 alone	 and	 to	 determine	 a	 subtoxic	 dose	 that	 did	 not	 affect	 cell	
proliferation	after	72	hours	of	culture	(data	not	shown).	The	each	metabolite	was	added	
to	HAEC	concomitantly	with	the	statin	IC50	treatment	and	HCMV	titers	were	quantified	
at	 6	 dpi	 in	 a	 TCID50	 assay.	 Reduction	 in	 HCMV	 titers	mediated	 by	 statins	was	 almost	
completely	abolished	when	MVA	was	added	to	the	cultures	(Figure	19).	Meanwhile,	CHO	
failed	 to	 reverse	 the	 anti‐CMV	 activity	 of	 all	 statins,	 whereas	 GGPP	 partially	 restored	
HCMV	titers	in	fluva‐	and	simvastatin‐treated	cultures.		
	
	
Figure	19:	The	anti‐CMV	activity	of	statins	in	HAEC	is	mediated	by	mevalonate	
products.	
HCMV	infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	
cultures	treated	with	the	statins	IC50	alone	or	co‐treated	with	CHO	(1	µM),	GGPP	(10	µM),	or	
MVA	(100	µM).	Results	are	expressed	in	relative	level	of	infection	compared	to	untreated	
cultures,	and	bars	represent	mean	values	±	SD	of	at	least	three	independent	experiments.	
	
These	results	demonstrate	that	the	anti‐CMV	activity	of	statins	directly	results	from	the	
inhibition	 of	 the	 HMG‐CoA	 reductase.	 The	 sterol	 branch	 of	 the	 mevalonate	 pathway	
seems	 unlikely	 to	 be	 involved	 in	 the	 anti‐CMV	 activity	 of	 statins,	 but	 given	 that	 the	
inhibition	of	the	isoprenoid	intermediates	play	a	significant	role	in	the	regulation	of	cell	
signaling	processes	[147],	HCMV	replication	may	be	affected	through	the	inhibition	of	an	
intracellular	process.	
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III. Cell	specificity	of	the	anti‐
cytomegalovirus	activity	of	statins	
The	 postulated	 role	 of	 the	 cellular	 isoprenoids	 intermediates	 in	 mediating	 the	 anti‐
HCMV	 activity	 triggers	 the	 question	 of	 the	 cell	 specificity	 of	 the	 anti‐CMV	 activity	 of	
statins.	Since	the	mechanism	seems	to	be	cell‐mediated	rather	than	virus	specific,	there	
is	a	possibility	that	the	anti‐CMV	activity	of	statins	will	be	cell	type	specific.	
HCMV	 can	 infect	 a	 remarkably	 broad	 range	 of	 cells	 within	 its	 host,	 including	
parenchymal	 cells	 and	 connective	 tissue	 cells	 of	 virtually	 any	 organ	 and	 various	
hematopoietic	cell	types.	Skin	or	lung	fibroblast	have	always	been	the	standard	cell	type	
for	 isolation	 and	 propagation	 of	 HCMV	 from	 patient	 samples,	 and	 are	 still	 the	 most	
efficient	producer	cell	 line	 irrespective	of	 the	virus	 strain	 [195].	Therefore,	 fibroblasts	
were	used	to	carry	out	most	studies	on	the	molecular	biology	and	replication	of	HCMV.	
Consistent	 with	 their	 susceptibility	 in	 vitro,	 fibroblasts	 are	 predominantly	 infected	
during	 acute	 HCMV‐infection,	 are	 a	 major	 population	 of	 cells	 permissive	 for	 HCMV	
replication	and	provide	the	platform	for	efficient	proliferation	of	the	virus	in	vivo[9].		
Evaluation	 of	 human	 lung	 fibroblast	 MRC‐5	 may	 reveal	 some	 potential	 cell‐specific	
differences	 and	provide	 some	 additional	 understanding	 of	 the	mechanism	of	 the	 anti‐
CMV	activity	of	statins.	
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1. Anti‐proliferative	activity	of	statins	in	fibroblasts	
	
	
Figure	20:	Anti‐proliferative	activity	of	statins	in	MRC‐5	after	a	72‐hour	drug	
exposure	period.	
Scatter	plots	of	the	statins	concentrations	responsible	for	50%	(IC50),	20%	(IC20)	or	no	cell	
growth	inhibition	(SD)	as	compared	with	untreated	culture.	Bar	represent	mean	±	SEM	of	at	
least	3	experiments.		
To	evaluate	the	anti‐CMV	activity	of	the	statins	on	the	human	lung	fibroblast	MRC‐5,	we	
first	performed,	as	for	HAEC,	preliminary	experiments	to	define	the	SD,	IC20	and	IC50	for	
all	 4	 statins	 using	 the	 alamarBlue®	 assay.	 Compare	 to	 EC,	 MRC‐5	 were	 slightly	 less	
sensitive	to	statins	(Figure	20).	The	mean	IC20	and	IC50	values	were	2‐	to	4‐	fold	higher	
than	 for	HAEC	with	 the	 same	 hierarchy	 of	 the	 anti‐proliferative	 activity.	 All	 lipophilic	
statins	doses	were	in	the	micromolar	range	whereas	pravastatin	IC50	reached	1	mM.		
	
2. Anti‐cytomegalovirus	activity	of	statins	in	fibroblasts	
We	 next	 established	 whether	 statins	 exhibit	 anti‐CMV	 activity	 in	 MRC‐5	 (Figure	 21).	
Despite	 higher	 titers	 in	 supernatants	 of	 control	 cultures	 (1x106	 TCID50	 mL‐1	 versus	
2x104	TCID50	mL‐1	 in	HAEC	at	an	MOI	of	1),	a	similar	dose‐dependent	 inhibition	of	the	
infectious	viral	particles	produced	in	statin‐treated	cultures	was	observed.	Except	with	
pravastatin,	no	significant	reduction	of	the	titers	were	noticed	with	the	SD.	At	the	IC20,	
atorva‐	 and	 simvastatin	 lowered	 HCMV	 titers	 by	 1	 log.	 Pravastatin	 and	 atorvastatin	
achieved	 a	 3.5	 log	 and	 2.3	 log	 reductions	 of	 the	 titers	 at	 the	 IC50	 while	 fluvastatin	
exhibited	fairly	limited	anti‐CMV	activity	on	MRC‐5	cultures.		
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Figure	21:	Statins	dose‐dependently	inhibit	HCMV	infectious	titers	in	MRC‐5.	
HCMV	infectious	titers	were	determined	in	supernatant	of	cultures	at	6	dpi	by	a	TCID50	
assay.	Results	are	expressed	in	TCID50	mL‐1	as	mean	values	±	SD	of	four	independent	
experiments.	
	
However, the determination of EC50 and EC90 revealed more discrepancy in the potency of the 
different statins (Table	4). Simva- and atorvastatin exhibited again the highest potency, with 
EC50 of ~0.16 µM	and	~0.46	µM respectively,	and	fairly comparable	EC90	(~1.5 µM	and	~1.6	
µM)	within	the	range	of	their	IC20.	Fluvastatin,	that	presented	similar	potency	in	HAEC	
than	 the	 2	 previous	 statins,	 was	 ~3 times less potent in MRC-5. Not surprisingly, 
pravastatin EC50 in MRC-5 was largely increased in comparison (~55 µM).	
Table	4:	In	vitro	anti‐proliferative	and	anti‐CMV	activity	of	statins	on	MRC‐5.	
Cell type Drug 
Anti-proliferative activitya (μM) Anti-CMV activityb (μM) 
SD IC20 IC50 EC50 EC90 
MRC-5 
Atorvastatin 0.1 1.5 5 0.46 ± 0.27 1.45 ± 0.57 
Fluvastatin 0.01 0.2 1 0.68 ± 0.37 4.08 ± 1.52 
Pravastatin 100 300 1000 55 ± 36 211 ± 116 
Simvastatin 0.1 1 3.5 0.16 ± 0.23 1.57  ± 1.04 
a Concentrations responsible for 50% (IC50), 20% (IC20) or no cell growth inhibition (SD or sub-
inhibitory dose) over a 72-hour period of time, as compared with untreated control cell growth. 	 
b EC50 and EC90 values determined by TCID50 assay. Nonlinear regression analysis was performed, 
and the resulting graphs were used to calculate the respective values. Results are expressed as means ± 
standard deviations of at least 3 independent experiments. 
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3. Effects	of	statin	treatment	on	HCMV	replication	cycle	
in	fibroblasts	
Considering	the	differences	in	the	replication	rate	of	HCMV	between	fibroblasts	and	EC	
as	well	as	the	reduced	anti‐CMV	activity	of	statins,	we	investigated	the	differences	in	the	
mechanism	of	the	anti‐CMV	activity.		
	
Figure	22:	Statins	only	partially	inhibit	the	expression	of	the	three	families	of	viral	
antigens	in	MRC‐5.	
Western	blot	analysis	of	viral	IE,	E	(pp52)	and	L	(pp65)	antigen	expression	between	1	and	5	
dpi	in	cultures	treated	with	the	statin	IC50.	β‐actin	was	used	as	a	loading	control.	One	
representative	experiment	out	of	three	is	shown.	
	
The	time‐course	relative	expression	of	the	IE,	E	and	L	antigens	from	1	to	5	dpi	revealed	
slight	differences	compared	to	EC	(Figure	22).	 In	control	cultures,	substantial	amounts	
of	both	E	and	L	antigens	were	detected	at	3	dpi,	highlighting	the	 increased	replication	
rate	 of	 HCMV	 in	 MRC‐5.	 As	 in	 HAEC	 statin	 treatment	 altered	 IE,	 E	 and	 L	 antigen	
expression,	 however,	 in	 MRC‐5	 accumulation	 of	 immediate‐early,	 early	 and	 late	 gene	
products	 was	 not	 abolished	 by	 atorva‐	 simva‐	 and	 pravastatin	 but	 only	 delayed,	 in	 a	
similar	manner	 than	with	 fluvastatin	 in	HAEC.	Consistently	with	 the	 reduced	effect	on	
the	titre	in	MRC‐5,	fluvastatin	only	slightly	affected	the	accumulation	of	immediate‐early,	
early	and	late	gene	products.	
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Figure	23:	The	anti‐CMV	activity	of	statins	persist	up	to	an	18	hpi	delay	of	
treatment	in	MRC‐5.		
MRC‐5	cultures	were	treated	with	the	atorva‐	or	simvastatin	IC50	at	various	time	points	
from	24	hours	prior	to	infection	(T‐24h)	up	to	36	hours	post	infection	(T+36h).	HCMV	
infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	cultures.		
Results	are	expressed	in	TCID50	mL‐1	as	mean	values	±	SD	of	two	independent	experiments.	
	
In	 delayed	 treatment	 experiments,	 similar	 results	 as	 for	 HAEC	 were	 obtained..	 The	
infectious	 titers	 revealed	 a	 maintained	 anti‐CMV	 activity	 of	 atorvastatin	 with	 a	
treatment	 delayed	 up	 to	 18	 hpi	 whereas	 simvastatin	 IC50	 already	 partially	 lost	 its	
antiviral	 effects	 when	 added	 at	 12	 hpi	 (Figure	 23).	 This	 earlier	 loss	 of	 the	 anti‐CMV	
activity	of	statins	was	in	accordance	with	the	faster	replication	of	HCMV	in	MRC‐5	and	
thus	the	earlier	expression	of	the	E	antigen.	Nevertheless,	this	emphasizes	the	important	
role	of	the	IE	antigen	inhibition	in	the	mechanism	of	the	anti‐CMV	activity	in	fibroblasts.		
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4. Isoprenoids	mediate	the	anti‐cytomegalovirus	activity	
of	statins	in	fibroblasts	
We	 finally	 performed	 metabolite	 rescue	 experiments	 in	 MRC‐5.	 Consistent	 with	 the	
outcome	observed	in	HAEC,	MVA	almost	completely	counteracted	the	anti‐CMV	activity	
of	 atorva‐,	 prava‐	 and	 simvastatin,	 whereas	 CHO	 showed	 no	 effect	 (Figure	 24).	
Interestingly,	 whereas	 in	 HAEC,	 GGPP	 only	 partly	 counteract	 the	 anti‐CMV	 activity	 of	
simvastatin,	it	strongly	abolished	it	for	all	statins,	almost	to	a	similar	extent	as	MVA.	This	
major	difference	between	the	two	cell	 types	could	either	be	due	to	a	 limited	uptake	of	
GGPP	 in	HAEC	 compare	 to	MRC‐5,	 or	 indicating	 a	 significant	 role	 of	 the	 down‐stream	
isoprenoids	intermediate	in	the	mechanism	of	the	anti‐CMV	activity	of	statins	in	MRC‐5.	
	
	
Figure	24:	Isoprenoid	co‐treatment	also	counteracts	the	anti‐CMV	activity	of	
statins	in	MRC‐5.	
HCMV	infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	
cultures	treated	with	the	statins	IC50	alone	or	co‐treated	with	CHO	(1	µM),	GGPP	(10	µM),	or	
MVA	(100	µM).	Results	are	expressed	in	relative	level	of	infection	compared	to	untreated	
cultures,	and	bars	represent	mean	values	±	SD	of	three	independent	experiments.	
	
Altogether,	the	anti‐CMV	activity	of	statins	did	not	depend	on	the	cell	type,	although	we	
could	observe	 some	differences	 in	 the	 replication	rate	of	 the	virus	 in	 the	different	 the	
cell	types.	
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IV. Potential	clinical	benefits	of	the	anti‐
cytomegalovirus	activity	of	statins	
1. Anti‐cytomegalovirus	activity	and	daily	treatment	
with	statin	
All	 the	results	 reported	up	 to	now	have	been	achieved	using	one	single	dose	of	 statin,	
used	 to	 treat	 cultures	 24‐hours	 before	 infection.	 However,	 statins	 are	 commonly	
prescribed	as	a	daily	treatment	with	“standard	dose”	defined	to	reduce	LDL	cholesterol	
by	30–45%	or	to	prevent	cardiovascular	events	(ie,	atorvastatin	10–20	mg,	 fluvastatin	
40–80	mg,	 pravastatin	 40	mg	 and	 simvastatin	 20–40	mg)	 [111].	 According	 to	 clinical	
pharmacokinetics	 studies,	 statins	 are	 rapidly	 absorbed	 following	 oral	 administration,	
and	 reach	 their	 plasma	 peak	 concentration	 within	 4	 hours	 [130].	 Although	 the	
elimination	 half‐life	 of	 all	 statins	 except	 atorvastatin	 is	 very	 short	 (0.5–3	 hours),	 the	
reported	pharmacokinetic	 half‐lives	 of	 statins	 do	not	 correspond	with	 the	 duration	 of	
their	pharmacodynamic	effect	(approximately	24	hours).	On	the	other	hand,	due	to	 its	
long	elimination	half‐life	(15‐30	hours)	and	the	presence	of	detectable	plasma	levels	of	
active	 metabolites	 for	 a	 prolonged	 period	 of	 time	 (>24	 hours),	 atorvastatin	 can	
accumulate	 in	 the	 plasma,	 achieving	 a	 steady‐state	 drug	 concentration	 after	 multiple	
doses	[196,	197].	
Thus,	we	decided	to	evaluate	the	potential	of	repeated	doses	of	statins	on	the	anti‐CMV	
activity.	HAEC	and	MRC‐5	cultures	were	treated	in	parallel	with	a	single	dose	of	atorva‐,	
fluva‐	and	simvastatin	 (SD,	 IC20	or	 IC50)	or	with	multiple	doses	 (SD,	 IC20)	added	either	
every	other	day	(EOD)	or	every	day	(Daily).	Multiples	IC50	doses	were	not	evaluated	for	
their	anti‐CMV	activity	because	of	 their	 increased	cellular	 toxicity.	Figure	25	describes	
the	infectious	titers	determined	in	supernatants	of	HAEC	cultures	at	6	dpi.	As	expected,	
we	 observed	 a	 dose‐dependent	 inhibition	 of	 HCMV	 titers	 in	 cultures	 treated	 with	 a	
single	dose	of	 statin,	with	atorvastatin	exhibiting	 the	strongest	anti‐CMV	activity	at	all	
doses,	 followed	 by	 simvastatin,	 and	 fluvastatin	 having	 limited	 effect.	 Surprisingly,	
repeated	treatment	with	the	SD	of	the	three	statin	did	not	result	in	a	reduction	of	HCMV	
titers,	neither	given	EOD	nor	as	daily	treatment.	In	contrast,	we	observed	an	increased	
anti‐CMV	activity	with	repeated	IC20	doses	of	the	three	statins,	a	daily	treatment	being	
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more	 efficient	 than	 EOD	 treatment.	 Interestingly,	 both	 fluva‐	 and	 simvastatin	 daily	
treatment	achieved	greater	reductions	of	HCMV	titers	as	compared	to	a	single	IC50	dose.	
	
	
Figure	25:	Additive	anti‐CMV	activity	of	multiple	doses	of	statins	in	HAEC.	
HCMV	infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	HAEC	
cultures	treated	with	the	indicated	doses	of	statin	either	one	time	only	(Single),	every	other	
day	(EOD)	or	every	day	(Daily).	Results	are	expressed	in	TCID50	mL‐1	as	mean	values	±	SD	of	
two	independent	experiments.	
	
Similar	results	were	observed	on	MRC‐5.	As	 for	HAEC	repeated	treatment	with	 the	SD	
did	 not	 affected	 HCMV	 titers	 (Figure	 26).	 With	 atorva‐	 and	 simvastatin	 IC20,	 the	
treatment	 EOD	 strongly	 improved	 the	 titer	 reduction	 obtained	 with	 a	 single	 dose,	
reaching	similar	effect	than	the	IC50	with	a	daily	treatment.	However,	no	additivity	of	the	
anti‐CMV	activity	of	fluvastatin	was	observed	(data	not	shown).	
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Figure	26:	Multiple	doses	treatment	with	statins	in	MRC‐5.	
HCMV	infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	MRC‐5	
cultures	treated	with	the	indicated	doses	of	statin	either	one	time	only	(Single),	every	other	
day	(EOD)	or	every	day	(Daily).	Results	are	expressed	in	TCID50	mL‐1.	One	representative	
experiment	out	of	three	is	shown.	
Considering	the	limited	concentration	of	statins	in	the	blood	of	patients	following	a	daily	
medication,	it	is	interesting	to	observe	an	additive	anti‐CMV	activity	with	small	doses	of	
statins.	Nevertheless,	these	findings	required	to	be	confirmed	in	vivo.		
	
2. Statins	enhance	the	anti‐cytomegalovirus	activity	of	
ganciclovir	
The	 risk	 for	 developing	 HCMV	 resistance	 to	 antiviral	 drugs	 is	 greater	 in	 transplants	
recipients	requiring	long‐term	suppressive	anti‐CMV	therapy.	Long	term	management	of	
infection	may	be	 facilitated	by	 the	administration	of	compounds	with	non‐overlapping	
mechanisms	of	action	as	combination	therapy	[198].	GCV	targets	the	activity	of	the	viral	
DNA	polymerase,	during	the	early	phase	of	infection	[89].	By	contrast,	we	showed	that	
statins	affect	HCMV	replication	as	early	as	the	IE	phase,	suggesting	that	statins	and	GCV	
do	not	share	the	same	mechanism	of	action.	Therefore,	we	wondered	if	a	combination	of	
the	two	compounds	would	result	in	a	synergistic	anti‐CMV	activity.		
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Figure	27:	Statins	potentiate	anti‐CMV	activity	of	ganciclovir	in	HAEC.	
HCMV	infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	(A)	
HAEC	or	(B)	MRC‐5	cultures	treated	with	the	indicated	doses	of	statin	alone	(w/o)	or	co‐
treated	with	ganciclovir	(5	µM	for	HAEC,	1	µM	for	MRC‐5)	(w/	GCV).	Results	are	expressed	in	
TCID50	mL‐1	as	mean	values	±	SD	of	at	least	two	independent	experiments.	
	
Preliminary	 experiments	 were	 designed	 to	 evaluate	 the	 toxicity	 of	 GCV	 in	 an	
AlamarBlue®	assay	and	to	define	a	dose	of	GCV	that	would	only	slightly	reduce	(about	1	
log)	HCMV	titers	(data	not	shown).	It	is	to	be	noted	that	the	dose	of	GCV	resulting	in	a	1	
log	decrease	of	HCMV	 titers	 in	MRC‐5	was	5	 times	 lower	 than	 for	HAEC	 (1	and	5	µM,	
respectively).	Cultures	were	treated	with	the	3	doses	of	statins	24	hours	prior	to	HCMV	
infection	at	an	MOI	of	1	and	subsequently	co‐treated	or	not	with	GCV.	HCMV	titers	were	
determined	at	6	dpi	in	a	TCID50	assay.		
In	both	cell	types,	statins	enhanced	the	anti‐CMV	activity	of	GCV	(Figure	27	A	&	B).	No	
sign	 of	 antagonism	 was	 observed	 and	 interestingly,	 some	 combination	 resulted	 in	
greater	effects	than	expected.	In	general,	combination	of	GCV	with	the	SD	or	the	IC20	of	
every	statin	resulted	in	an	addition	of	the	anti‐CMV	activities.	In	HAEC,	atorvastatin	IC20	
particularly	enhanced	GCV	effects.	While	 fluvastatin	 IC50	alone	had	only	a	 limited	anti‐
CMV	activity	(0.9	log	reduction),	combination	with	GCV	further	reduced	the	titers	by	2.4	
log.		
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These	 observations	 suggest	 that	 combination	 of	 statins	 with	 GCV	 resulted	 in	
interference	 with	 two	 distinct	 steps	 of	 the	 viral	 replication	 cycle	 and	 could	 at	 some	
specific	doses	result	in	a	synergy	of	the	antiviral	activities.	
3. Susceptibility	of	ganciclovir‐resistant	HCMV	strain	to	
statins	
To	confirm	the	previous	hypothesis,	we	used	a	HCMV	strain	resistant	to	GCV,	the	HCMV	
mutant	 strain	 pp6,	 derived	 from	 an	 AIDS	 patient	 characterized	with	 both	M460I	 and	
M460V	mutations	of	the	UL97	gene	[175].	Being	a	fibrotropic	strain	with	a	low	efficiency	
of	infection	in	EC,	we	evaluated	the	susceptibility	of	the	pp6	strain	in	MRC‐5,	in	parallel	
with	the	wild	type	fibrotropic	TB40/F	strain.	MOI	were	adapted	for	both	strains	to	reach	
similar	 HCMV	 titers	 in	 the	 supernatants	 of	 control	 cultures	 at	 6dpi	 (Figure	 28).	 As	
expected,	increasing	doses	of	GCV	strongly	affect	HCMV	titers	of	the	TB40/F	strain	with	
a	3.5	log	reduction	with	25	µM	whereas	the	pp6	strain	replication	is	hardly	reduced.	The	
EC90	 values	 were	 	 ̴2.9  µM	 for	 TB40/F	 and	 	 ̴140  µM	 for	 pp6,	 corroborating	 the	 GCV‐
resistance	 of	 the	 strain	 (Table	 5).	 Note	 that	 EC50s	 are	 in	 agreement	 with	 previously	
reported	results	[199].	
	
Figure	28:	Statins	affect	both	pp6	GCV‐resistant	and	TB40/F	wild‐type	fibrotropic	
strains.	
HCMV	infectious	titers	were	determined	at	6	dpi	by	a	TCID50	assay	in	supernatant	of	
cultures	treated	with	ganciclovir	(5,	15	and	25	µM),	atorva	or	simvastatin	(IC20	or	IC50)	and	
infected	with	the	pp6	GCV‐resistant	strain	(MOI=0.1)	or	with	the	wild	type	TB40/F	strain	
(MOI=0.5).	Results	are	expressed	in	TCID50	mL‐1	as	mean	values	±	SD	of	two	independent	
experiments.	
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In	contrast,	both	strains	showed	similar	susceptibility	to	statin	treatment.	Atorvastatin	
achieved	a	comparable	drop	of	both	pp6	and	TB40/F	titers.	Both	EC50	were	under	1	µM	
and	 the	 EC90	 equivalent	 to	 atorvastatin	 IC20	 (Table	 4).	 Simvastatin	 exhibit	 a	 lower	
potency	 when	 compare	 to	 atorvastatin,	 with	 TB40/F	 being	 slightly	 more	 susceptible	
than	 pp6,	 with	 respective	 EC90	 of	 1.8	 µM	 and	 2.4	 µM.	 Both	 statins	 demonstrate	 an	
equipotent	inhibitory	effect	on	the	TB40/F	strain	than	GCV.		
Table	5:	HCMV	resistant	strain	to	GCV	remains	susceptible	to	statins.	
 
pp6 TB40/F 
EC50 EC90 EC50 EC90 
Ganciclovir 7.3 140 1.2 2.9 
Atorvastatin 0.80 1.6 0.96 1.5 
Simvastatin 1.7 2.4 1.2 1.8 
         Data are in μM. 
Thus,	we	 showed	 that	HCMV	 resistance	 to	 GCV	 resulting	 from	mutations	 of	 the	UL97	
genes	does	not	protect	the	strain	against	the	anti‐CMV	activity	of	statins.		 	
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 	Discussion	
HCMV	 infections	 in	 immunocompromised	 host,	 in	 particular	 in	 SOT	 recipients,	 are	 a	
major	 cause	 of	 morbidity	 and	 mortality.	 Today,	 all	 available	 treatments	 for	 systemic	
HCMV	infection	are	directly	aimed	at	a	specific	viral	process,	the	replication	of	the	viral	
DNA.	The	characteristic	latent	infection	often	requires	a	long‐term	drug	exposure	of	the	
patients	during	a	major	period	of	immunosuppression,	which	is	associated	with	relevant	
side‐effects.	 In	 addition,	 the	 limited	 bioavailability	 of	 these	 compounds	 increases	 the	
risk	of	ongoing	viral	replication	resulting	from	insufficient	antiviral	drug	exposure	and	
the	 emergence	 of	 drug	 resistance.	 In	 the	 absence	 of	 vaccines	 against	 HCMV	 and	
considering	the	drawbacks	limiting	the	use	of	current	antiviral	drugs,	there	is	an	urgent	
need	for	new	therapeutic	approaches	for	the	management	of	acute	HCMV	disease.	
Because	 viruses	 require	 the	 host‐cell	 environment	 to	 replicate,	 one	 effective	 strategy	
consists	 in	 targeting	 a	 host‐cell	 function	 that	 will	 affect	 the	 virus	 replication,	 with	 a	
known	 drug	 having	 a	 good	 safety	 profile.	 Statins	 are	 a	well‐tolerated	 and	 extensively	
studied	 group	 of	 drugs,	 primarily	 used	 as	 hypolipidemic	 agents	 for	 reducing	 plasma	
cholesterol	 levels	 and,	 consequently,	 for	 preventing	 CVD.	 Interestingly,	 favorable	
outcomes	of	statins	in	CVD	as	well	as	in	other	diseases	states	(for	a	complete	review,	see	
[147])	have	been	associated	with	several	pleiotropic	effects	that	are	unrelated	to	their	
cholesterol	 lowering	 properties.	 Among	 other,	 antiviral	 properties	 are	 potentially	
playing	an	 important	role	 in	mediating	 these	effects.	So	 far,	 little	 is	known	about	 their	
potential	against	HCMV.	
In	 2004,	 Potena	 et	 al.	 reported	 that	 fluvastatin	 treatment	 of	 human	 umbilical	 vein	
endothelial	cells	 (HUVEC)	restrained	HCMV	replication	 in	vitro	 [163].	Although	statins	
were	 shown	 to	 display	 cholesterol‐lowering	 as	 well	 as	 cholesterol‐independent	 class	
effects,	their	pharmacological	differences	(structural,	biochemical	and	thermodynamic)	
raises	 the	 question	 of	 an	 anti‐cytomegalovirus	 class	 effect.	 We	 thus	 decided	 to	
investigate	 for	 the	 in	 vitro	 antiviral	 activity	 of	 various	 statins	 against	 HCMV,	 in	 two	
relevant	cell	types	during	HCMV	infection,	in	human	aortic	endothelial	cells	(HAEC)	and	
in	human	lung	fibroblasts	(MRC‐5).	
We	compared	the	anti‐CMV	activity	of	4	statins,	based	on	doses	that	would	comparably	
affect	 the	 proliferative	 response	 of	 the	 treated	 cells.	 Statins	 revealed	 a	 similar	 anti‐
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proliferative	activity	 in	both	HAEC	and	MRC‐5,	 the	second	being	slightly	 less	 sensitive	
(Table	3	&	Table	4).	Fluvastatin	exhibited	the	stronger	activity	followed	by	simvastatin	
and	 atorvastatin,	 with	 IC20	 under	 0.5	 µM	 and	 IC50	 under	 2	 µM	 in	 HAEC.	 These	
concentrations	 are	 in	 accordance	 with	 previously	 published	 data	 and	 reveal	 an	
increased	 sensitivity	 of	 HAEC	 to	 statins	 as	 compared	 to	 HUVEC	 [179].	 In	 contrast,	
pravastatin	 IC50	were	about	200	times	higher	 than	 the	other	statins	 in	both	HAEC	and	
MRC‐5.	This	apparent	discrepancy	might	be	explained	by	differences	in	physicochemical	
properties	 of	 statins.	 Indeed,	 lipophilic	 statins	 (atorva‐,	 fluva‐	 and	 simvastatin)	 are	
expected	 to	 easily	 and	 passively	 penetrate	 into	 in	 vitro	 cultured	 cells	 while	 the	
hydrophilicity	 of	 pravastatin	 should	 prevent	 its	 nonselective	 passive	 diffusion	 across	
cellular	membranes	[200].	However,	it	is	generally	agreed	that	the	lipophilicity	does	not	
entirely	predict	 the	ability	of	statins	to	exert	 their	pleiotropic	effects	 [130,	201].	Some	
cells,	 such	 as	 primary	 cultured	 skeletal	 myofibres	 isolated	 from	 rat,	 express	 known	
organic	anion	membrane	transporters,	which	can	 internalize	hydrophilic	statins	[202].	
Our	 findings	 support	 the	 notion	 that	 significant	 differences	 exist	 among	 statins	 with	
respect	to	their	anti‐proliferative	activity	as	well	as	to	their	pleiotropic	effects.	
Atorva‐,	 fluva‐	 and	 simvastatin	 not	 only	 exhibited	 a	 similar	 anti‐proliferative	 activity,	
but	 they	 also	 demonstrated	 an	 equipotent	 anti‐CMV	 activity	 in	 HAEC	 (Table	 3).	 We	
assessed	EC50	and	EC90	for	each	statin	based	on	the	reduction	of	HCMV	infectious	titers	
determined	in	the	supernatants	of	cultures	at	6	dpi.	In	HAEC,	we	found	EC50	to	be	in	the	
range	 of	 their	 respective	 SD,	within	 the	 sub	micromolar	 range	 for	 the	 three	 lipophilic	
statins	(<30	nM).	In	addition,	the	EC90	appeared	to	be	under	their	respective	IC20,	with	
the	exception	of	fluvastatin	that	reached	the	IC50	level.	In	contrast,	higher	concentrations	
were	 required	 to	 achieve	 similar	 effects	 in	 MRC‐5	 (Table	 4).	 Whereas	 atorva‐	 and	
simvastatin	EC50	and	EC90	did	range	between	 their	 respective	 IC20	and	 IC50,	 fluvastatin	
EC90	 reached	 four‐time	 its	 IC50.	 Not	 surprisingly,	 pravastatin	 exhibited	 a	 similar	 low	
potency	in	term	of	anti‐CMV	activity	like	for	anti‐proliferative	activity,	with	an	EC50	over	
50	µM	 in	MRC‐5.	Altogether,	 simvastatin	was	 shown	 to	be	 the	most	 effective	 statin	 to	
inhibit	HCMV	replication	in	both	HAEC	and	MRC‐5,	with	atorvastatin	exhibiting	almost	a	
similar	 potential	 while	 fluvastatin	 was	 slightly	 less	 efficient.	 In	 contrast	 pravastatin	
displayed	 no	 effective	 response	 as	 assessed	 by	 the	 large	 concentrations	 of	 statin	
required.	
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We	confirmed	previously	published	data	of	Potena	et	al.,	reporting	the	in	vitro	anti‐CMV	
activity	of	fluvastatin	treatment	on	HUVEC	where	a	reduction	of	HCMV	yield	by	65%	was	
obtained	using	a	dose	of	fluvastatin	of	0.1	µM	while	a	dose	of	0.2	µM	reduced	the	yield	
by	more	than	90%	[163].	In	this	setting,	the	viral	yield	reduction	was	associated	with	a	
stable	reduction	of	IE	antigen	expression	over	a	period	of	14	days.	We	obtained	a	similar	
reduction	of	 the	viral	 yield	 after	6	dpi,	with	 an	EC90	of	0.3	µM	 in	HAEC.	However,	 the	
expression	of	 the	different	proteins	 of	 the	 viral	 replication	 cycle	was	only	moderately	
impacted	 in	 our	 hands.	 Inhibition	 of	 IE	 antigen	 expression	 was	 only	 delayed	 and	
accumulation	 reoccurred	 after	 4	 dpi	 (Figure	 18).	 This	 apparent	 discrepancy	 may	 be	
attributable	to	differences	in	the	treatment	protocol,	as	in	our	setting,	cells	were	treated	
with	 statins	 only	 once,	 24	 hours	 prior	 to	 infection,	 whereas	 Potena	 et	 al.	 repeatedly	
treated	the	cultures	every	72	hours	by	adding	fresh	fluvastatin.	Consistently,	fluvastatin	
exhibit	 a	 shorter	 half‐life	 (0.5‐2.3	 hours)	 as	 compared	 to	 the	 other	 lipophilic	 statins	
(atorva‐	and	simvastatin),	which	could	explain	why	only	repeated	treatment	resulted	in	
a	similar	sustained	inhibition	of	viral	protein	expression	achieve	with	a	single	treatment	
by	the	other	statin	[130].		
The	 hypothesis	 of	 a	 cell	 specificity	 of	 the	 anti‐CMV	 activity	 of	 the	 statins	was	 raised,	
between	different	cell	types	as	well	as	within	EC	from	different	vascular	origins.	Indeed,	
EC	 are	 a	 highly	 diverse	 cell	 type	 according	 to	 anatomic	 location	 and	 tissue	 source.	
Although	 they	 share	 a	 large	 number	 of	 phenotypic	 similarities	 that	 reflect	 their	
involvement	 in	 common	 processes,	 they	 are	 widely	 diverse	 in	 terms	 of	 morphology,	
antigen	expression	as	well	as	gene	expression	profiles	 that	results	 from	tissue‐specific	
functions	[203].	In	particular,	DNA	array	analyses	show	that	micro‐	and	macrovascular	
ECs	vary	considerably	in	expression	levels	of	various	molecules	involved	in	HCMV	entry,	
such	 as	 integrins	 and	 epidermal	 growth	 factor	 receptors,	 resulting	 in	 different	
susceptibility	to	HCMV	infection	[204].	However,	not	only	did	we	and	others	observe	a	
similar	 anti‐CMV	 activity	 of	 fluvastatin	 in	 HAEC	 and	 HUVEC,	 but	 we	 also	 obtained	
equivalent	 anti‐CMV	 activity	 with	 the	 4	 statins	 in	 human	 cardiac	 microvascular	 EC	
during	preliminary	experiments	(data	not	shown).	We	could	thus	exclude	a	mechanism	
that	would	rely	on	a	tissue‐specific	function.		
Similarly,	the	cell	type	specificity	was	assessed	on	fibroblasts	where	certain	differences	
could	be	observed.	The	ranking	of	statins	potency	was	identical	to	the	one	seen	in	HAEC,	
however	the	concentrations	required	to	achieve	a	similar	anti‐proliferative	activity	were	
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3‐fold	 higher,	 and	 10‐fold	 higher	 for	 the	 anti‐CMV	 activity.	 Lipophilic	 statins	 are	
considered	to	penetrate	into	cells	by	passive	diffusion	across	cellular	membranes,	which	
should	 not	 largely	 differ	 between	 cell‐types	 [200].	 Thus	 these	 disparities	 could	 be	
attributed	 to	 the	 increased	metabolism	of	 fibroblasts.	 Indeed,	 the	proliferation	 rate	 of	
MRC‐5	 is	 twice	 higher	 than	 for	 HAEC	 (data	 not	 shown),	 while	 the	 replication	 rate	 of	
HCMV	in	fibroblasts	is	also	clearly	higher,	as	assessed	by	the	viral	titers	determined	in	
the	 supernatants	 of	 non‐treated	 cultures	 at	 6	 dpi	 (1x106	 TCID50	 mL‐1	 versus	 2x104	
TCID50	mL‐1	 in	HAEC	at	an	MOI	of	1)	(Figure	9	&	Figure	21).	Accordingly,	whereas	the	
expression	of	the	three	families	of	viral	antigens	was	completely	abolished	in	HAEC	by	
all	 statins	 except	 fluvastatin	 during	 a	 relative	 time	 course	 of	 expression	 over	 6	 dpi	
(Figure	18),	they	were	only	partially	inhibited	in	MRC‐5	(Figure	22),	with	a	similar	delay	
of	 the	 expression	 as	 observed	 in	 fluvastatin‐treated	 cultures	 of	HAEC.	 Consistently,	 in	
delayed	 treatment	 experiments	 the	 anti‐CMV	 activity	 of	 atorvastatin	 was	 mainly	
maintained	when	statins	were	added	to	the	cultures	up	to	24	hpi	in	HAEC	but	only	up	to	
18	 hpi	 in	 MRC‐5.	 However,	 the	 main	 difference	 we	 observed	 was	 related	 to	 the	
mediators	of	the	anti‐CMV	activity.		
The	potential	antiviral	activity	of	statins	has	been	investigated	for	a	number	of	viruses	
and	 rather	 diverse	 mechanisms	 have	 been	 identified.	 In	 Rotavirus	 and	 Dengue	 virus	
infections,	 the	 anti‐cholesterol	 effect	 explains	 how	 statins	 inhibit	 virus	 production	 via	
decreasing	virion	assembly	 [151,	166].	 In	 the	case	of	anti‐HCV	and	anti‐HIV‐1	activity,	
statin	effects	seem	dependent	on	derivatives	of	the	mevalonate	pathway,	such	as	GGPP	
(Table	 2)	 [152,	 167,	 168].	 Our	 study	 confirms	 previous	 findings	 that	 the	 anti‐CMV	
activity	of	statins	directly	resulted	from	the	inhibition	of	the	HMG‐CoA	reductase	since	
reduction	of	HCMV	titers	and	viral	antigens	expression	were	reversed	by	the	addition	of	
mevalonate	in	both	cell	types	(Figure	19,	Figure	24	&	data	not	shown)	[163].	Metabolite	
rescue	 experiments	 performed	with	 cholesterol	 suggest	 that	 the	 sterol	 branch	 of	 the	
mevalonate	 pathway	 is	 unlikely	 to	 be	 involved	 since	 the	 co‐treatment	 of	 statins	with	
water	 soluble	 cholesterol	 failed	 to	 restore	 the	anti‐CMV	activity	 in	HAEC	or	 in	MRC‐5.	
One	might	 argue	 that	 cholesterol	was	 not	 necessarily	 uptaken	 by	 cells	 in	 culture	 and	
thus	 cannot	 counteract	 statins	 effects.	 However,	 we	 failed	 to	 observe	 any	 significant	
modulation	 of	 the	 cellular	 cholesterol	 level	 in	 statin‐treated	 cultures	 of	 HAEC	 over	 a	
period	 of	 7	 days.	 Thus,	 even	 though	 the	de	novo	 synthesis	 of	 cellular	 cholesterol	was	
inhibited	by	statin	treatment,	cells	can	most	likely	balance	the	depletion	of	endogenous	
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cholesterol	via	uptake	from	lipoproteins	from	the	extracellular	milieu	through	receptor‐
mediated	mechanisms	 [205].	 In	 contrast,	 the	 isoprenoid	arm	of	 the	pathway	might	be	
implicated	in	the	anti‐CMV	activity	of	statins.	In	HAEC,	co‐treatment	with	GGPP	partially	
counteracted	the	inhibition	of	HCMV	titers	mediated	by	fluva‐	and	simvastatin,	but	not	
the	other	statins	(Figure	19).	However	in	MRC‐5,	the	anti‐CMV	activity	of	all	statins	was	
blocked.	Consistently,	a	recent	study	performed	on	a	model	of	murine	CMV	infection	of	
mouse	embryonic	fibroblast	cells	showed	that	simvastatin	exerts	a	dose‐dependent	anti‐
viral	activity	(EC50=2	µM)	that	was	shown	to	be	dependent	on	GGPP	inhibition	but	not	
cholesterol,	in	a	similar	series	of	metabolite	rescue	experiments	[206].		
So	far,	to	our	knowledge	none	of	the	HCMV	proteins	was	reported	to	be	prenylated,	 in	
contrast	 to	 the	 pseudorabies	 virus	 Us2	 tegument	 component	 [207].	 Even	 though	 the	
treatment	 of	 infected	 cells	 with	 lovastatin	 was	 shown	 to	 impair	 the	 Us2	 protein	
localization	 by	 preventing	 its	 proper	 membrane	 association,	 this	 protein	 was	 not	
required	 for	 in	 vitro	 replication	 and	 uninvolved	 into	 pseudorabies	 virus	 virulence.	 In	
addition,	 Desplanques	 et	 al.	 demonstrated	 that	 the	 statin‐mediated	 reduction	 of	
pseudorabies	 virus	 infectivity	 and	 stability	 of	 the	 provirus	 was	 associated	 with	 the	
reduction	 of	 cellular	 cholesterol	 [164].	 Thus,	 the	 anti‐CMV	 activity	 of	 statins	 is	 most	
likely	achieved	through	modification	of	a	host	cell	function.	By	interfering	with	several	
transcriptional	 and	 post‐transcriptional	 events	 mevalonate	 metabolites	 affect	 various	
biological	processes.	We	looked	for	a	modulation	of	the	cell	cycle	progression	of	statin‐
treated	 HAEC	 (Figure	 12)	 that	 might	 impair	 HCMV	 replication.	 However,	 in	 our	
experimental	 conditions	 a	 majority	 of	 HAEC	 was	 already	 into	 the	 G1	 phase	 that	 is	
necessary	for	a	proper	HCMV	replication	[187],	and	no	increase	of	the	fraction	of	cells	in	
G2	was	observed.	Isoprenoids	were	also	shown	to	be	involved	in	the	energy	metabolism	
regulation.	 Goto	 et	 al.	 showed	 that	 the	 isoprenoid	 FPP	 may	 serve	 as	 an	 endogenous	
agonist	 of	PPARγ,	 an	 isoform	of	 the	PPAR	subset	of	nuclear	 receptors,	which	binds	 to	
DNA	 and	 regulates	 gene	 expression	 in	 adipocytes	 [208].	 These	 authors	 also	
demonstrated	 that	 in	 the	 presence	 of	 lovastatin,	 both	 intracellular	 FPP	 levels	 and	
PPARγ‐target	 gene	 expressions	 were	 decreased.	 In	 a	 recent	 study,	 Rauwel	 et	 al.	
demonstrated	 that	 i)	 HCMV	 infection	 led	 to	 increased	 PPARγ	 activity	 and	 ii)	 PPARγ	
antagonist	treatment	provoked	a	drastic	decrease	in	HCMV	production	in	vitro	[209].	In	
addition,	by	regulating	the	expression	of	IE2	mRNA	PPARγ	seems	to	play	a	central	role	
in	HCMV	replication	in	a	way	that	depends	on	association	with	its	ligand.	Therefore,	the	
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anti‐CMV	 activity	 observed	 in	 our	 hands	 could	 be	 the	 result	 of	 a	 drastic	 reduction	 of	
available	 FPP	 in	 the	 cells,	 preventing	 the	 FPP/	 PPARγ	 ligand‐receptor	 association	
leading	to	a	severe	reduction	of	viral	protein	production.	
Potential	 clinical	 benefits	 of	 statin	 therapy	 in	 the	management	of	 acute	CMV	 infection	
can	only	be	achieved	if	clinical	pharmacokinetics	of	statins	are	consistent	with	effective	
concentrations	 for	 anti‐CMV	 activity.	We	determined	 in	 vitro	EC50	 in	HAEC	within	 the	
sub	 micromolar	 range	 for	 atorva‐,	 fluva‐	 and	 simvastatin	 (<30	 nM)	 with	 a	 single	
treatment	 (Table	 3).	 These	 concentrations	 are	 in	 the	 range	 of	 the	 plasma	 peak	
concentration	(Cmax)	reported	for	a	40	mg	oral	dose	of	the	three	lipophilic	statins	and	
thus	in	accordance	with	therapeutically	relevant	concentrations	[130].	It	is	however	to	
be	noted,	 that	 the	EC50	determined	 in	 fibroblasts	 can	only	be	achieve	with	 fluvastatin,	
which	 is	 the	only	statin	reported	 to	have	a	Cmax	 in	 the	micromolar	range.	Fluvastatin	
could	thus	be	potentially	considered	as	being	the	more	clinically	relevant.	Yet	fluvastatin	
also	 present	 the	 shortest	 elimination	 half‐life	 of	 available	 statins	 (0.5–2.3	 hours	
compared	to	15‐30	hours	for	atorvastatin)	resulting	in	a	relatively	short‐lived	systemic	
exposure.	 In	vitro	 repeated	treatment	with	statins	significantly	 increased	the	anti‐CMV	
activity	as	compare	to	a	single	dose	treatment	(Figure	25	&	Figure	26).	Consistently,	a	
recent	 study	 performed	 on	 a	 model	 of	 murine	 infection	 showed	 that	 daily	
administration	of	simvastatin	in	mice	resulted	in	a	1	 log	decrease	of	murine	CMV	viral	
titers	in	multiple	organs	after	4	dpi	[206].	This	study	confirmed	the	in	vivo	potential	of	
statins	 in	 control	 of	 CMV	 infection,	 however,	 additional	 studies	 will	 be	 necessary	 to	
evaluate	 the	 anti‐CMV	 profiles	 of	 the	 different	 statins,	 alone,	 but	 also	 in	 combination	
therapy	with	conventional	antiviral	drugs.		
Several	 reports	 have	 already	 described	 the	 ability	 of	 statin	 treatment	 to	 potentiate	
conventional	antiviral	 therapy.	 In	vitro,	 statins	were	shown	 to	potentiate	 the	anti‐HCV	
activity	of	several	HCV	inhibitors	[158,	169].	Delang	et	al.	established	that	combination	
of	 mevastatin	 or	 simvastatin	 with	 IFN‐α	 or	 HCV	 polymerase	 or	 protease	 inhibitors	
resulted	in	an	additive	antiviral	activity.	Moreover,	the	authors	demonstrated	that	statin	
treatment	also	prevented	or	at	least	delayed	the	emergence	of	drug	variants	resistant	to	
a	STAT‐C	inhibitor.	We	evaluated	the	potential	of	statins	in	combination	therapy	with	a	
low	dose	of	GCV,	the	first‐line	treatment	of	HCMV	infection.	At	most	concentrations,	the	
anti‐CMV	 activity	 of	 statins	 was	 additive	 in	 combination	 with	 GCV	 and	 a	 possible	
potentiation	 was	 observed	 with	 certain	 doses	 (Figure	 27),	 although	 additional	
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experiments	will	 be	 required	 to	properly	 assess	 a	potential	 synergy	of	 the	 two	drugs.	
Nevertheless,	these	findings	suggest	a	possible	benefit	with	the	use	of	statins	therapy	in	
vivo,	in	combination	with	GCV.	On	the	contrary,	maribavir,	a	CMV	UL97	kinase	inhibitor	
in	development,	was	shown	to	antagonize	the	anti‐CMV	effect	of	GCV	[210].	
A	major	 concern	 in	 the	management	 of	 systemic	HCMV	 infection	 is	 the	 emergence	 of	
drug	resistance	to	different	anti‐CMV	drugs	and	in	particular	to	GCV.	Long‐term	and/or	
repeated	therapy	in	 immunocompromised	patients	with	severe	HCMV	disease	 is	a	risk	
factor	 for	 the	 emergence	 of	 mutant	 virus	 strains,	 not	 only	 resistant	 to	 GCV,	 but	 also	
cross‐resistance	to	either	or	both	second	line	agents,	resulting	in	treatment	failure	[88,	
89].	We	demonstrated	here	that	atorva‐	and	simvastatin	exhibits	comparable	anti‐CMV	
activity	 than	 GCV	 in	 the	 wild‐type	 TB40/F	 strain	 (EC50	 ̴1	 µM),	 confirming	 previous	
finding	in	human	and	murine	CMV		[199,	 206].	Moreover,	mutations	of	 the	HCMV	UL97	
genes	(M460I	and	M460V)	conferring	GCV	resistance	to	HCMV	did	not	prevent	the	anti‐
viral	activity	of	atorva‐	and	simvastatin,	EC50	and	EC90	being	similar	in	both	susceptible	
and	resistant	 strains	 (Figure	28	&	Table	5).	Mutations	of	 the	gene	coding	 for	 the	viral	
UL97	kinase	appears	in	more	than	80%	of	resistant	clinical	isolates	from	patients	who	
receive	GCV	as	 initial	 therapy	[88,	211].	Being	consistently	 found	in	 limited	number	of	
codons,	UL97	resistant	mutations	are	relatively	easy	to	evaluate.	Resistance	to	the	UL54	
pol	 gene	 coding	 for	 the	 viral	 DNA	 polymerase	 are	 less	 common	 and	 more	 likely	 to	
emerge	after	prolonged	GCV	exposure	[212].	However,	not	only	pol	mutations	are	more	
varied	and	widely	distributed,	but	also	all	known	GCV	resistance	mutations	in	pol	confer	
cross‐resistance	to	CDV	and/or	FOS.	 It	will	 then	be	of	major	 interest	 to	 i)	evaluate	the	
sensibility	of	such	strains	to	statins	 in	vitro	as	well	as	 in	vivo,	 ii)	to	evaluate	whether	a	
combine	statin‐GCV	treatment	can	prevent	the	emergence	of	the	different	kind	of	GCV‐
resistant	HCMV	strain.	
Another	multifunctional	 compound	 has	 recently	 been	 demonstrated	 as	 a	 non‐specific	
protective	agent	against	HCMV	infection.	Artesunate	is	a	semi‐synthetic	derivative	of	the	
natural	 product	 artemisinin,	 highly	 effective	 in	 the	 treatment	 of	 severe	 malaria,	
particularly	as	a	part	of	combination	therapies	with	other	antimalarial	drugs.	Along	with	
a	high	safety	and	tolerability	profile	demonstrated	in	clinic,	artesunate	reveals	a	broad	
spectrum	antiviral	activity	against	herpesviruses	and	in	particular	against	HCMV	[213].	
Not	only	artesunate	does	inhibit	the	replication	of	laboratory	and	clinical	drug‐resistant	
and	 drug‐sensitive	 HCMV	 strains	 in	 vitro	 at	 therapeutically	 relevant	 doses,	 but	 the	
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antiviral	 activity	 of	 artesunate	was	 also	 additive	when	used	 in	 combination	with	 each	
one	 of	 conventional	 anti‐HCMV	 drugs	 [214].	 Artesunate	 is	 suspected	 to	 inhibit	 the	
HCMV‐induced	DNA	binding	activities	of	both	NF‐κB	and	SP1	transcription	factors,	thus	
interfering	with	critical	host‐cell‐type	and	metabolism	requirements	in	the	initial	step	of	
HCMV	replication.	Importantly,	artesunate	has	been	successfully	used	for	the	treatment	
of	 a	 patient	 developing	 a	 drug‐resistant	 CMV	 infection	 during	 preemptive	 antiviral	
therapy	(with	foscarnet)	after	stem	cell	transplantation	[215].	
With	 a	 similar	 profile	 as	 artesunate;	 a	 good	 safety	 profile;	 a	 potent	 in	 vitro	 anti‐CMV	
activity	alone	and	in	combination	with	approved	antiviral	drugs;	a	cellular	rather	than	a	
viral	 target	 limiting	the	risk	of	development	of	drug	resistance;	we	believe	that	statins	
could	offer	a	new	therapeutic	option	for	the	management	of	acute	CMV	disease.		
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 Conclusion	and	outlook	
This	work	demonstrates	 for	 the	 first	 time	that	various	statins	exert	a	potent	anti‐CMV	
activity	in	vitro	at	therapeutically	relevant	concentrations.	Statins	inhibit	the	expression	
of	three	families	of	viral	antigens,	the	immediate‐early,	early	and	late	antigens,	resulting	
in	 a	 major	 decrease	 of	 the	 production	 and	 release	 of	 infectious	 viral	 particles	 in	
endothelial	 cells	 and	 in	 fibroblasts.	 These	 effects	 appear	 to	 results	 from	 the	 specific	
inhibition	of	a	host‐cell	 functions	mediated	via	 the	 inhibition	of	 the	 isoprenoid	arm	of	
the	mevalonate	pathway.	Furthermore,	statins	demonstrated	a	similar	anti‐CMV	activity	
in	susceptible	and	resistant	HCMV	strains	as	well	as	beneficial	outcome	in	co‐treatment	
with	ganciclovir.		
These	 findings	 support	 further	 investigations	 on	 statins	 in	 vivo,	 in	 a	murine	model	 of	
CMV	infection,	and	in	a	clinical	setting.	The	evaluation	of	combination	therapy	of	specific	
antiviral	 drugs	 with	 statins,	 as	 part	 of	 a	 cholesterol‐lowering	 regimen	 or	 an	 anti‐
atherosclerosis	therapy,	might	offer	great	benefit	in	the	long‐term	management	of	HCMV	
infections	 in	 patients	 such	 as	 SOT	 transplants	 recipients	 or	 patients	 with	 AIDS.	
Combination	 therapy	could	not	only	 increase	the	efficacy	of	current	anti‐CMV	therapy,	
but	also	prevent	the	emergence	of	HCMV‐resistant	infection.	
In	 addition,	 we	 believe	 that	 the	 identification	 of	 host‐cell	 functions	 essential	 for	 viral	
replication	might	offer	a	new	reservoir	of	target	for	the	development	of	new	therapeutic	
strategies.	
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2. Abbreviations	
CDV:	cidofovir		
CHO:	cholesterol	
Cmax:	plasma	peak	concentration	
CRP:	C‐reactive	protein	
CVD:	cardiovascular	diseases	
dpi:	days	post	infection	
ds:	double‐stranded		
E:	early	
EBV:	Epstein‐Barr	virus	
EC:	endothelial	cells	
EGFR:	epidermal	growth	factor	receptor		
FOS:	foscarnet	
FPP:	farnesyl	pyrophosphate	
GCV:	ganciclovir	
GGPP:	geranylgeranyl	pyrophosphate	
HAART:	highly	active	antiretroviral	therapy	
HC:	hypercholesterolemia		
HCMV:	human	cytomegalovirus	
HCV:	hepatitis	C	virus	
HMG‐CoA:	3‐hydroxy‐3‐methylglutaryl	coenzyme	A	
hpi:	hours	post	infection	
ICAM‐1:	intracellular	adhesion	molecule	
IE	immediate	early		
IFN:	interferon	
IV:	intravenous		
L:	late	
LDL:	low‐density	lipoprotein	
LFA‐1:	leukocyte	function‐associated	antigen‐1	
MCP:	major	capsid	protein		
MCP:	major	capsid	protein		
MIEP:	major	immediate	early	enhancer‐promoter	
min:	minute	
MOI:	multiplicity	of	infection	
MVA:	mevalonate	
MβCD:	methyl‐β‐cyclodextin	
ORF:	open	reading	frames	
pp:	phosphoprotein	(ex:pp65)	
SOT:	solid	organ	transplantation.	
UL:	unique	long	segment		
US:	unique	short	segment	
VSMC:	vascular	smooth	muscle	cells		 	
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3. Publication	
The	major	 findings	of	 this	work	have	been	 submitted	 for	publication	 in	 the	 Journal	of	
Medical	Virology	as	a	research	article.		
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